PROSTHETIC DEVICES HAVING ENHANCED OSTEOGENIC PROPERTIES

Reference to Related Applications

This application is a continuation-in-part of copending U.S. application Serial No. 07/841,646, filed 2/21/92, which is a continuation-in-part of U.S. Application Serial Nos. :

1) 07/827,052, filed January 28,1992, a divisional of USSN 07/179,406, filed April 8, 1988, now US 4,968,590;

2) 07/579,865, filed September 7, 1990, a divisional of USSN 07/179,406; 3) 07/621,849, filed December 4, 1990, a divisional of USSN 07/232,630, filed August 15, 1988, now abandoned, that was a continuation-in-part of 07/179,406;

4) 07/621,988, filed December 4, 1990, a divisional of 07/315,342 filed February 23, 1989, now US 5,011,691 and which is a continuation-in-part of 07/232,630;

5) 07/810,560, filed December 20, 1991, a continuation of 07/660,162, filed February 22, 1991, now abandoned, that was a continuation of 07/422,699, filed October 17, 1989, now abandoned, that was a continuation-in-part of 07/315,342;

6) 07/569,920, filed August 20, 1990, now abandoned, that was a continuation-in-part of 07/422,699 and 07/483,913, which is continuation-in-part of 07/422,613, filed October 17, 1989, now US 4,975,526 and which is a continuation-in-part of 07/315,342; 7) 07/600,024, filed October 18, 1990, a continuation-in-part of 07/569,920;

8) 07/599,543, filed October 18, 1990, a continuation-in- part of 07/569,920; 9) 07/616,374, filed November 21, 1990, a divisional of 07/422,613; and 10) 07/483,913, filed February 22, 1990.

Background of the Invention

Regeneration of skeletal tissues is thought to be regulated by specific protein factors that are naturally present within bone matrix. When a bone is damaged, these factors stimulate cells to form new cartilage and bone tissue which replaces or repairs lost or damaged bone. Regeneration of bone is particularly important where prosthetic implants are used without bonding cement to replace diseased bone, as in hip replacement. In these cases, formation of a tight bond between the prosthesis and the existing bone is very important, and successful function depends on the interaction between the implant and the bone tissue at the interface.

Bone healing can be stimulated by one or more osteogenic proteins which can induce a developmental cascade of cellular events resulting in endochondral bone formation. Proteins stimulating bone growth have been referred to in the literature as bone morphogenic proteins, bone inductive proteins, osteogenic proteins, osteogenin or osteoinductive proteins.

U.S. 4,968,590 (November 6, 1990) discloses the purification of "substantially pure" osteogenic protein from bone, capable of inducing endochondral bone formation in a mammal when implanted in the mammal in association with a matrix, and having a half maximum activity of at least about 25 to 50 nanograms per 25 milligrams of implanted matrix. Higher activity subsequently has been shown for this protein, e.g., 0.8-1.0 ng of osteogenic protein per mg of implant matrix, as disclosed in U.S. Patent 5,011,691. This patent also disclosed a consensus DNA sequence probe useful for identifying genes encoding osteogenic proteins, and a number of human genes encoding osteogenic proteins identified using the consensus probe, including a previously unidentified gene referred to therein as "OP1" (osteogenic protein-1). The consensus probe also identified DNA

sequences corresponding to sequences termed BMP-2 Class I and Class II ("BMP2" and "BMP4" respectively) and BMP3 in International AppI. No. PCT/US87/01537. The osteogenic proteins encoded by these sequences are referred to herein as "CBMP2A," "CBMP2B", and "CBMP3", respectively. U.S. 5,011,691 also defined a consensus "active region" required for osteogenic activity and described several novel biosynthetic constructs using this consensus sequence which were capable of inducing cartilage or bone formation in a mammal in association with a matrix.

These and other researchers have stated that successful implantation of the osteogenic factors for endochondral bone formation requires that the proteins be associated with a suitable carrier material or matrix which maintains the proteins at the site of application. Bone collagen particles which remain after demineralization, guanidine extraction and delipidation of pulverized bone have been used for this purpose. Many osteoinductive proteins are useful cross-species. However, demineralized, delipidated, guanidine-extracted xenogenic collagen matrices typically have inhibited bone induction in vivo. Sampath and Reddi (1983) Proc. Natl. Acad. Sci. USA, 80; 6591-6594. Recently, however, Sampath et al. have described a method for treating demineralized guanidine-extracted bone powder to create a matrix useful for xenogenic implants. See, U.S. 4,975,526 (December 4, 1990). Other useful matrix materials include for example, collagen; homopolymers or copolymers of glycolic acid, lactic acid, and butryic acid, including derivatives thereof; and ceramics, such as hydroxyapatite, tricalcium phosphate and other calcium phosphates. Combinations of these matrix materials also may be useful.

Orthopedic implants have traditionally been attached to natural bone using bone cement. More recently, cementless prostheses have been used, in which the portion of the prosthesis that contacts the natural bone is coated with a

porous material. M. Spector, J. Arthroplasty, 2(2) :163-176 (1987); and Cook et al., Clin. Orthoped. and Rel. Res., 232: 225-243 (1988). Cementless fixation is preferred because biological fixation of the prosthesis is stronger when osseointegration is achieved. The porous coatings reportedly stimulate bone ingrowth resulting in enhanced biological fixation of the prosthesis. However, there are several problems with porous-coated prostheses. For example, careful prosthetic selection is required to obtain a close fit with the bone to ensure initial mechanical stabilization of the device, and surgical precision is required to ensure initial implant-bone contact to promote bone ingrowth. Porous coated implants have not resulted in bone ingrowth in some instances, for example, in porous coated tibial plateaus used in knee replacements. A prosthetic implant that results in significant bone ingrowth and forms a strong bond with the natural bone at the site of the join would be very valuable.

The current state of the art for the anchoring of embedded implants such as dental implants also is unsatisfactory. Typically, dental implant fixation first requires preparing a tooth socket in the jawbone of an individual for prosthesis implantation by allowing bone ingrowth into the socket void to fill in the socket. This preparatory step alone can take several months to complete. The prosthesis then is threaded into the new bone in the socket and new bone is allowed to regrow around the threaded portion of the implant embedded in the socket. The interval between tooth extraction and prosthetic restoration therefore can take up to eight months. In addition, threading the prosthesis into bone can damage the integrity of the bone. Prosthetic dental implants that can improve osseointegration and reduce the time and effort for fixation would be advantageous.

Summary of the Invention

The present invention relates to a method of enhancing the growth of bone at the site of implantation of a prosthesis to form a bond between the prosthesis and the existing bone. As used herein, a prosthesis is understood to describe the addition of an artificial part to supply a defect in the body. The method involves coating or otherwise contacting all or a portion of the prosthesis that will be in contact with bone with a substantially pure osteogenic protein. The prosthesis first may be coated with the osteogenic protein and then implanted in the individual at a site wherein the bone tissue and the surface of the prosthesis are maintained in close proximity for a time sufficient to permit enhanced bone tissue growth between the tissue and the implanted prosthesis. Alternatively, the site of implantation first may be treated with substantially pure osteogenic protein and the prosthesis then implanted at the treated site such that all or a portion of the prosthesis is in contact with the osteogenic protein at the site, and the prosthesis, the osteogenic protein and the existing bone tissue are maintained in close proximity to one another for a time sufficient to permit enhanced bone tissue growth between the tissue and the prosthesis. The osteogenic protein associated with the implanted prosthesis stimulates bone growth around the prosthesis and causes a stronger bond to form between the prosthesis and the existing bone than would form between the prosthesis and the bone in the absence of the protein.

In a preferred embodiment of the present method a prosthetic device, such as an artificial hip replacement device, e.g., a metallic device made from titanium, for example, is first coated with an osteogenic material which induces bone ingrowth. When the device is subsequently implanted into the individual, bone growth around the site of the implant is enhanced, causing a strong bond to form

between the implant and the existing bone. The present method results in enhanced biological fixation of the prosthesis in the body, which is particularly important for weight bearing prostheses. Prostheses defining a microporous surface structure are locked in place as bone formation occurs within the micropores. The metal or ceramic prosthesis may itself define such a structure, or the prosthesis may be coated to provide an adherent porous surface. Materials useful for this purpose include, for example, collagen, homopolymers of glycolic acid, lactic acid, and butyric acid, including derivatives thereof; and ceramics such as hydroxyapatite, tricalcium phosphate or other calcium phosphates. Combinations of these materials may be used. A substantially pure osteogenic protein is then bound to the uncoated or coated prosthesis. Alternatively, the osteogenic protein can be mixed with the coating material, and the mixture adhered onto the surface of the prosthesis.

In another embodiment of the present invention, osteogenic protein combined with a matrix material is packed into an orifice prepared to receive the prosthetic implant. The surface of the implant also may be coated with osteogenic protein, as described above. The implant has a shape defining one or more indentations to permit bone ingrowth. The indentations are preferably transverse to the longitudinal axis of the implant. In general, the longitudinal axis of the implant will be parallel to the longitudinal axis of the bone which has been treated to receive the implant. New bone grows into the indentations thereby filling them, integrates with the surface of the implant as described above, and integrates with existing bone. Thus, the prosthesis can be more tightly fixed into the orifice, and "latched" or held in place by bone growing into the indentations, and by osseointegration of new bone with the surface of the implant, both of which are stimulated by the osteogenic protein.

In a specific embodiment, a dental implant is used to replace missing teeth. The implant typically comprises a threaded portion which is fixed into the jawbone and a tooth portion configured to integrate with the rest of the patient's teeth. The implant is coated with osteogenic protein (with or without a matrix or carrier) and threaded or screwed into a tooth socket in the jawbone prepared to receive it (e.g., bone has been allowed to grow into and fill the socket void. ) In a particularly preferred embodiment, the socket is prepared to receive the implant by packing the void with a bone growth composition composed of osteogenic protein dispersed in a suitable carrier material. The combination of osteogenic protein and carrier is referred to herein as an "osteogenic device." The osteogenic protein promotes osseointegration of the implant into the jawbone without first requiring bone growth to fill the socket, and without requiring that the prosthesis be threaded into existing bone, which may weaken the integrity of the the existing bone. Accordingly, the time interval between tooth extraction and prosthetic restoration is reduced significantly. It is anticipated that prosthetic restoration may be complete in as little time as one month. In addition, the ability of the osteogenic protein to promote osseointegration of the prosthesis will provide a superior anchor.

A prosthetic device coated with the above osteogenic protein also is the subject of the present invention. All or a portion of the device may be coated with the protein. Generally, only the portion of the device which will be in contact with the existing bone will be coated.

The present method and device results in enhanced biological fixation of the prosthesis. A strong bond is formed between the existing bone and the prosthesis, resulting in improved mechanical strength at the joining

site. Higher attachment strength means that the prosthesis will be more secure and permanent, and therefore will be more comfortable and durable for the patient.

Brief Description of the Drawing

The sole Figure of the drawing schematically depicts a cross-sectional view of a portion of a prosthesis implanted in a femur and illustrates the latching action of bone ingrowth in accordance with an embodiment of the invention.

Detailed Description of the Invention

The present invention relates to a method for enhancing osseointegration between a prosthesis and natural bone in an individual at the site of implantation of the prosthesis. The method involves providing a prosthesis to a site of implantation together with substantially pure osteogenic protein such that the osteogenic protein is in contact with all or a portion of the implanted prosthesis. The protein promotes osseointegration of the prosthesis and the bone, resulting in a strong bond having improved tensile strength.

Osteogenic proteins which are useful in the present invention are substantially pure osteogenically active dimeric proteins. As used herein "substantially pure" means substantially free of other contaminating proteins having no endochondral bone formation activity. The protein can be either natural-sourced protein derived from mammalian bone or recombinantly produced proteins, including biosynthetic constructs. The natural-sourced proteins are characterized by having a half maximum activity of at least 25 to 50 ng per 25 mg of demineralized protein extracted bone powder, as compared to rat demineralized bone powder.

The natural-sourced osteogenic protein in its mature, native form is a glycosylated dimer having an apparent molecular weight of about 30 kDa as determined by SDS-PAGE. When reduced, the 30 kDa protein gives rise to two glycosylated peptide subunits having apparent molecular weights of about 16 kDa and 18 kDa. In the reduced state, the protein has no detectable osteogenic activity. The unglycosylated protein, which also has osteogenic activity, has an apparent molecular weight of about 27 kDa. When reduced, the 27 kDa protein gives rise to two unglycosylated polypeptides having molecular weights of about 14 kDa to 16 kDa. The recombinantly-produced osteogenic protein describes a class of dimeric proteins capable of inducing endochondral bone formation in a mammal comprising a pair of

polypeptide chains, each of which has an amino acid sequence sufficiently duplicative of the sequence of the biosynthetic constructs or COP-5 Or COP-7, (SEQ. ID NOS.3 and 4), such that said pair of polypeptide chains, when disulfide bonded to produce a dimeric species is capable of inducing endochondral bone formation in a mammal. As defined herein, "sufficiently duplicative" is understood to describe the class of proteins having endochondral bone activity as dimeric proteins implanted in a mammal in association with a matrix, each of the subunits having at least 60% amino acid sequence homology in the C-terminal cysteine-rich region with the sequence of OPS (residues 335 to 431, SEQ. ID No. 1). "Homology" is defined herein as amino acid sequence identity or conservative amino acid changes within the sequence, as defined by Dayoff, et al.. Atlas of Protein Sequence and Structure; vol.5, Supp.3, pp.345-362, (M.O. Dayoff, ed. Nat'l Biomed. Research Fdn., Washington, D.C., 1979.) Useful sequences include those comprising the C-terminal sequences of DPP (from Drosophila), Vgl (from Xenopus), Vgr-1 (from mouse), the OPl and OP2 proteins, the CBMP2, CBMP3, and CBMP4 proteins (see U.S. Pat. No. 5,011,691 and U.S. Application Serial No. 07/841,646 by Oppermann et al., filed February 21, 1992, the disclosures of both of which are hereby incorporated by reference, as well as the proteins referred to as BMP5 and BMP6 (see WO90/11366, PCT/US90/01630. ) A number of these proteins also are described in WO88/00205, U.S. Patent No. 5,013,649 and WO91/18098. Table I provides a list of the preferred members of this family of osteogenic proteins.

TABLE I - OSTEOGENIC PROTEIN SEQUENCES hOPl - DNA sequence encoding human OPl protein (Seq. ID No. 1 or 3). Also referred to in related applications as "OPl", "hOP-1" and "OP-1".

OPl - Refers generically to the family of osteogenically active proteins produced by expression of part or all of the hOPl gene. Also referred to in related applications as "OPl" and OP-1".

hOPl-PP - Amino acid sequence of human OPl protein

(prepro form), Seq. ID No. 1, residues 1-431. Also referred to in related applications as "0P1-PP" and "OPP".

0Pl-18Ser - Amino acid sequence of mature human OPl protein, Seq. ID No. 1, residues 293-431. N-terminal amino acid is serine. Originally identified as migrating at 18 kDa on SDS-PAGE in COS cells. Depending on protein glycosylation pattern in different host cells, also migrates at 23kDa, 19kDa and 17kDa on SDS-PAGE. Also referred to in related applications as "0P1-18".

OPS - Human OPl protein species defining the conserved 6 cysteine skeleton in the active region (97 amino acids, Seq. ID No. 1, residues 335-431). "S" stands for "short".

0P7 - Human OPl protein species defining the conserved 7 cysteine skeleton in the active region (102 amino acids, Seq. ID No. 1, residues 330-431).

OPl-16Ser - N-terminally truncated mature human OPl protein species. (Seq. ID No. 1, residues 300-431). N-terminal amino acid is serine; protein migrates at 16kDa or 15kDa on

SDS-PAGE, depending on glycosylation pattern, Also referred to in related applications as "0P-16S".

Pl-16Leu - N-terminally truncated mature human OPl protein species, Seq. ID No. 1, residues 313-431. N-terminal amino acid is leucine; protein migrates at 16 or 15kDa on SDS-PAGE, depending on glycosylation pattern. Also referred to in related applications as "0P- 16L".

Pl-16Met - N-terminally truncated mature human OPl protein species, Seq. ID No. 1, residues 315- 431. N-terminal amino acid is methionine; protein migrates at 16 or 15kDa on SDS-PAGE, depending on glycosylation pattern. Also referred to in related applications as "0P- 16M".

Pl-16Ala - N-terminally truncated mature human OPl protein species, Seq. ID No. 1, residues 316- 431. N-terminal amino acid is alanine, protein migrates at 16 or 15 kDa on SDS-PAGE, depending on glycosylation pattern. Also referred to in related applications as "0P- 16A".

Pl-16Val - N-terminally truncated mature human OPl protein species, Seq. ID No. 1, residues 318- 431. N-terminal amino acid is valine; protein migrates at 16 or 15 kDa on SDS-PAGE, depending on glycosylation pattern. Also referred to in related applications as "0P- 16V".

mOPl DNA encoding mouse OPl protein, Seq. ID No. 8, Also referred to in related applications as "mOP-1".

mOPl-PP - Prepro form of mouse protein, Seq. ID No. 8, residues 1-430. Also referred to in related applications as "mOP-l-PP".

mOPl-Ser - Mature mouse OPl protein species (Seq. ID No. 8, residues 292-430). N-terminal amino acid is serine. Also referred to in related applications as "mOPl" and "mOP-1".

mOP2 DNA encoding mouse OP2 protein, Seq. ID No. 12. Also referred to in related applications as "mOP-2".

mOP2-PP - Prepro form of mOP2 protein, Seq. ID No. 12, residues 1-399. Also referred to in related applications as "mOP-2-PP".

mOP2-Ala - Mature mouse OP2 protein, Seq. ID No. 12, residues 261-399. N-terminal amino acid in alanine. Also referred to in related applications as "mOP2" and "mOP-2".

hOP2 DNA encoding human OP2 protein, Seq. ID No. 10. Also referred to in related applications as "hOP-2".

hOP2-PP - Prepro form of human OP2 protein, Seq. ID No. 10, res. 1-402). Also referred to in related applications as "hOP-2-PP".

hOP2-Ala - Possible mature human 0P2 protein species: Seq. ID No. 10, residues 264-402. Also referred to in related applications as "hOP-2".

hOP2-Pro - Possible mature human 0P2 protein species: Seq. ID No. 10, residues 267-402. N-terminal amino acid is proline. Also referred to in related applications as "hOP-2P".

hOP2-Arg - Possible mature human OP2 protein species: Seq. ID No. 10, res. 270-402. N-terminal amino acid is arginine. Also referred to in related applications as "hOP-2R".

hOP2-Ser - Possible mature human OP2 protein species: Seq. ID No. 10, res. 243-402. N-terminal amino acid is serine. Also referred to in related applications as "hOP-2S".

Vgr-l-fx C-terminal 102 amino acid residues of the murine "Vgr-1" protein (Seq. ID No. 7).

CBMP2A C-terminal 101 amino acid residues of the human BMP2A protein. (Residues 296-396 of Seq. ID No. 14) .

CBMP2B C-terminal 101 amino acid residues of the human BMP2B protein. (Seq. ID No. 18).

BMP3 Mature human BMP3 (partial sequence, Seq. ID No. 16. See U.S. 5,011,691 for C-terminal 102 residues, "CBMP3.")

BMP5-fx C-terminal 102 amino acid residues of the human BMP5 protein. (Seq ID No. 20).

BMP6-fx C-terminal 102 amino acid residues of the human BMP6 protein. (Seq ID No. 21).

COP5 Biosynthetic ostegenic 96 amino acid sequence (Seq. ID No. 3).

COP7 Biosynthetic osteogenic 96 amino acid sequence (Seq. ID No. 4) .

DPP-fx C-terminal 102 amino acid residues of the Drosophila "DPP" protein (Seq. ID No. 5).

Vgl-fx C-terminal 102 amino acid residues of the Xenopus "Vgl" protein (Seq. ID No. 6).

The members of this family of proteins share a conserved six or seven cysteine skeleton in this region (e.g., the linear arrangement of these C-terminal cysteine residues is conserved in the different proteins.) See, for example, OPS, whose sequence defines the six cysteine skeleton, or OP7, a longer form of OPl, comprising 102 amino acids and whose sequence defines the seven cysteine skeleton. ) In addition, the OP2 proteins contain an additional cysteine residue within this region.

This family of proteins includes longer forms of a given protein, as well as species and allelic variants and biosynthetic mutants, including addition and deletion mutants and variants, such as those which may alter the conserved C-terminal cysteine skeleton, provided that the alteration still allows the protein to form a dimeric species having a conformation capable of inducing bone formation in a mammal when implanted in the mammal in association with a matrix. In addition, the osteogenic proteins useful in devices of this invention may include forms having varying glycosylation patterns and varying

N-termini, may be naturally occurring or biosynthetically derived, and may be produced by expression of recombinant DNA in procaryotic or eucaryotic host cells. The proteins are active as a single species (e.g., as homodimers), or combined as a mixed species.

A particularly preferred embodiment of the proteins useful in the prosthetic devices of this invention includes proteins whose amino acid sequence in the cysteine-rich C-terminal domain has greater than 60% identity, and preferably greater than 65% identity with the amino acid sequence of OPS.

In another preferred aspect, the invention comprises osteogenic proteins comprising species of polypeptide chains having the generic amino acid sequence herein referred to as "OPX" which accommodates the homologies between the various identified species of the osteogenic OPl and OP2 proteins, and which is described by the amino acid sequence of Sequence ID No. 22.

In still another preferred aspect, the invention comprises nucleic acids and the osteogenically active polypeptide chains encoded by these nucleic acids which hybridize to DNA or RNA sequences encoding the active region of OPl or OP2 under stringent hybridization conditions. As used herein, stringent hybridization conditions are defined as hybridization in 40% formamide, 5 X SSPE, 5 X Denhardt's Solution, and 0.1% SDS at 37°C overnight, and washing in 0.1 X SSPE, 0.1%.SDS at 50°C.

The invention further comprises nucleic acids and the osteogenically active polypeptide chains encoded by these nucleic acids which hybridize to the "pro" region of the OPl or OP2 proteins under stringent hybridization conditions. As used herein, "osteogenically active polypeptide chains" is understood to mean those polypeptide chains which, when dimerized, produce a protein species having a conformation such that the pair of polypeptide chains is capable of

inducing endochondral bone formation in a mammal when implanted in a mammal in association with a matrix or carrier.

Given the foregoing amino acid and DNA sequence information, the level of skill in the art, and the disclosures of U.S. Patent 5,011,691 and published PCT specification US 89/01469, published October 19, 1989, the disclosures of which are incorporated herein by reference, various DNAs can be constructed which encode at least the active domain of an osteogenic protein useful in the devices of this invention, and various analogs thereof (including species and allelic variants and those containing genetically engineered mutations), as well as fusion proteins, truncated forms of the mature proteins, deletion and addition mutants, and similar constructs. Moreover, DNA hybridization probes can be constructed from fragments of any of these proteins, or designed de novo from the generic sequence. These probes then can be used to screen different genomic and cDNA libraries to identify additional osteogenic proteins useful in the prosthetic devices of this invention.

The DNAs can be produced by those skilled in the art using well known DNA manipulation techniques involving genomic and cDNA isolation, construction of synthetic DNA from synthesized oligonucleotides, and cassette mutagenesis techniques. 15-100mer oligonucleotides may be synthesized on a DNA synthesizer, and purified by polyacrylamide gel electrophoresis (PAGE) in Tris-Borate-EDTA buffer. The DNA then may be electroeluted from the gel. Overlapping oligomers may be phosphorylated by T4 polynucleotide kinase and ligated into larger blocks which may also be purified by PAGE.

The DNA from appropriately identified clones then can be isolated, subcloned (preferably into an expression vector), and sequenced. Plasmids containing sequences of interest then can be transfected into an appropriate host cell for

protein expression and further characterization. The host may be a procaryotic or eucaryotic cell since the former's inability to glycosylate protein will not destroy the protein's orphogenic activity. Useful host cells include E. coli, Saccharomyces, the insect/baculovirus cell system, myeloma cells, CHO cells and various other mammalian cells. The vectors additionally may encode various sequences to promote correct expression of the recombinant protein, including transcription promoter and termination sequences, enhancer sequences, preferred ribosome binding site sequences, preferred mRNA leader sequences, preferred signal sequences for protein secretion, and the like.

The DNA sequence encoding the gene of interest also may be manipulated to remove potentially inhibiting sequences or to minimize unwanted secondary structure formation. The recombinant osteogenic protein also may be expressed as a fusion protein. After being translated, the protein may be purified from the cells themselves or recovered from the culture medium. All biologically active protein forms comprise dimeric species joined by disulfide bonds or otherwise associated, produced by folding and oxidizing one or more of the various recombinant polypeptide chains within an appropriate eucaryotic cell or in vitro after expression of individual subunits. A detailed description of osteogenic proteins expressed from recombinant DNA in E. coli is disclosed in U.S. Serial No. 422,699 filed October 17, 1989, the disclosure of which is incorporated herein by reference. A detailed description of osteogenic proteins expressed from recombinant DNA in numerous different mammalian cells is disclosed in U.S. Serial No. 569,920 filed August 20, 1990, the disclosure of which is hereby incorporated by reference.

Alternatively, osteogenic polypeptide chains can be synthesized chemically using conventional peptide synthesis techniques well known to those having ordinary skill in the

art. For example, the proteins may be synthesized intact or in parts on a solid phase peptide synthesizer, using standard operating procedures. Completed chains then are deprotected and purified by HPLC (high pressure liquid chromatography). If the protein is synthesized in parts, the parts may be peptide bonded using standard methodologies to form the intact protein. In general, the manner in which the osteogenic proteins are made can be conventional and does not form a part of this invention.

The osteogenic proteins useful in the present invention are proteins which, when implanted in a mammalian body, induce the developmental cascade of endochondral bone formation including recruitment and proliferation of mesenchymal cells, differentiation of progenitor cells, cartilage formation, calcification of cartilage, vascular invasion, bone formation, remodeling and bone marrow differentiation. The osteopenic protein in contact with the present prostheses can induce the full developmental cascade of endochondral bone formation at the site of implantation essentially as it occurs in natural bone healing.

Prostheses which can be used with the present method include porous or non-porous orthopedic prostheses of the types well known in the art. Such prostheses are generally fabricated from rigid materials such as metals, including for example, stainless steel, titanium, molybdenum, cobalt, chromium and/or alloys or oxides of these metals. Such oxides typically comprise a thin, stable, adherent metal oxide surface coating. The prostheses are preferably formed from or coated with porous metals to permit infiltration of the bone, but non-porous materials also can be used. Porous metallic materials for use in prostheses are described, for example, by Spector in J. Arthroplasty, 2(2) :163-176 (1987), and by Cook et al. in Clin. Orthoped. and Rel. Res., 232:225-243 (1988), the teachings of both of which are hereby incorporated herein by reference. Metallic

prostheses may be used for major bone or joint replacement and for repairing non-union fractures, for example, where the existing bone has been destroyed by disease or injury.

In a preferred embodiment of the present device and method, the prosthesis is coated with a material which enhances bone ingrowth and fixation, in addition to the protein. Materials which are useful for this purpose are biocompatible, and preferably in vivo biodegradable and non- immunogenic. Such materials include, for example, collagen, hydroxyapatite, homopolymers or copolymers of glycolic acid lactic acid, and butyric acid and derivatives thereof, tricalcium phosphate or other calcium phosphates, metal oxides, (e.g., titanium oxide), and demineralized, guanidine extracted bone.

The present coated prostheses are prepared by applying a solution of the protein, and optionally, hydroxylapatite or other material to all or a portion of the prosthesis. The protein can be applied by any convenient method, for example, by dipping, brushing, immersing, spraying or freeze-drying. Hydroxylapatite is preferably applied by a plasma spraying process. The protein is preferably applied by immersing the prostheses in a solution of the protein under conditions appropriate to induce binding or precipitation of the protein from solution onto the implant. The amount of protein which is applied to the implant should be a concentration sufficient to induce endochondral bone formation when the prosthesis is implanted in the recipient. Generally a concentration in the range of at least 5μg protein per 3.4cm ² surface area is sufficient for this purpose. If hydroxylapatite or other carrier material is used, it is applied to the prosthesis in an amount required to form a coating of from about 15μ to about 60μ thick. A layer about 25μ thick of hydroxylapatite has been used to improve implant fixation, as shown in the exemplification.

In one aspect, the prosthesis comprises a device configured for insertion into an orifice prepared to receive the prosthesis. In this embodiment, as illustrated in the Figure, the interior of a bone 10 is hollowed out in preparation for insertion of the implant 12. The implant has a contoured surface design 14 defining plural indentations 16 to permit ingrowth of bone into the indentations. The indentations are preferably transverse to the longitudinal axis 18 of the implant. The contoured portion to be inserted in the orifice may be coated with osteogenic protein as described above. Osteogenic protein combined with a matrix material 20 is packed into the orifice with the prosthetic implant, thereby surrounding it. Stimulated by the osteogenic protein, new bone grows into the indentations 16 and becomes integrated with the surface of the implant 12 and with preexisting bone 10 as described above. Thus, the prosthesis is both mechanically and biologically fixed in place, and axial movement of the implant relative to the bone requires shearing of bone tissue. Matrix material 20 can be any of the materials described above for coating the prosthesis for enhancing bone growth and fixation, e.g., collagen, hydroxyapatite, homopolymers or copolymers of glycolic acid lactic acid, and butyric acid and derivatives thereof, tricalcium phosphate or other calcium phosphates, metal oxides and demineralized, guanidine extracted bone. Matrix materials for use with osteogenic proteins which can be used in the present embodiment are those described, for example, in U.S. Patent 5,011,691 and in copending U.S. patent application Serial No. 07/841,646 by Oppermann et al., filed February 21, 1992, the teachings of which are hereby incorporated by reference.

The prothesis illustrated in the Figure is particularly useful for dental and other implants where at last part of the prosthesis is to be embedded into bone tissue. Packing the orifice, e.g., tooth socket, with an "osteogenic

device," e.g., osteogenic protein in combination with a matrix material, provides a solid material in which to embed the prosthesis without requiring that the device be threaded into existing bone. Moreover, the osteogenic protein stimulates endochondral bone formation within the socket and into and around the implant, thereby obviating the previously required step of first allowing bone ingrowth into the socket in order to provide a suitable surface into which to implant the prosthesis. Accordingly, using the method and devices of the invention, strong fixation of an implanted prosthesis may be achieved in a fraction of the time previously required, significantly shortening the time interval between tooth extraction and prosthetic restoration. In addition, this treatment may expand the use of implant therapy and enhance success rates by eliminating a surgical procedure, reducing the amount of bone lost following tooth extraction, permitting the insertion of longer implants and minimizing prosthetic compromises necessitated by alveolar ridge resorption.

The invention will be further illustrated by the following Exemplification which is not intended to be limiting in any way.

EXEMPLIFICATION

Example 1

Metal Implant Fixation

Cylindrical implants 18mm in length and 5.95 + 0.05mm in diameter were fabricated from spherical Co-Cr-Mo particles resulting in a pore size of 250-300μm and a volume porosity of 38-40%. A highly crystalline, high density and low porosity hydroxylapatite (HA) coating was applied by plasma spray process to one-half of the length of each of the implants. The coating thickness was 25 μm and did not alter the porous coating morphology.

In the initial study, three implants were treated with a partially purified bovine OP (bOP) preparation. The bOP was naturally sourced OP extracted from cortical bone and partially purified through the Sephacryl-300 HR step in the purification protocol as described in Sampath et al. (1990), J. Biol. Chem., 265: 13198-13205. 200μl aliquots of 4 M guanidine-HCl, 50 mM Tris-HCl, pH 7.0, containing approximately 80 μg bOP were added to each implant in an eppendorf tube. After overnight incubation at 4°C the protein was precipitated and the implant washed with 80% ethanol. The implants were subsequently freeze dried. Two implants without bOP served as the controls.

The implants were evaluated in one skeletally mature adult mongrel dog (3-5 years old, 20-25Kg weight) using the femoral transcortical model. Standard surgical techniques were used such that the animal received the five implants in one femur. At three weeks the dog was sacrificed and the femur removed.

The harvested femur was sectioned transverse to the long axis such that each implant was isolated. Each implant was sectioned in half to yield one HA-coated and one uncoated push-out sample. Interface attachment strength was determined using a specifically designed test fixture. The implants were pushed to failure with a MTS test machine at a displacement rate of 1.27 mm/minute. After testing, all samples were prepared for standard undecalcified histologic and microradiographic analyses. The sections (4 sections from each implant) were qualitatively examined for the type and quality of tissue ingrowth, and quantitatively evaluated for % bone ingrowth with a computerized image analysis system. The mechanical and quantitative histological data is shown in Table II.

TABLE II METAL IMPLANTS - bOP

3 WEEKS

HA-Coated Uncoated

Interface Shear Strength, MPa

Control 9.70 3.40 (n=2) (n=2)

Protein 10.75 4.08 (bOP) (n=3) (n= )

Percent Bone Ingrowth

Control 42.56 37.82 (n=4) (n=4)

Protein 51.66 46.38 (bOP) (n=4) (n=4)

Both the mechanical and histological data suggested that bOP enhanced osseointegration of the implants. Both the HA-coated and uncoated implants showed an increase of shear strength and bone ingrowth compared with untreated controls. Moreover, the HA-coated implants appeared to show significant enhancement compared to the uncoated implant. The histological sections directly showed a greater number of cells between the metal pores.

The positive results of the initial implant study prompted a more detailed study. Twenty-seven implants were treated with a recombinant human OPl protein. The OPl protein was produced by transformed CHO cells. Details for the recombinant production of OPl are disclosed in USSN 841,646, incorporated hereinabove by reference. The protein was purified to contain as the major species the protein designated OPl-18Ser (Seq. ID No. 1, residues 293-431), and about 30% truncated forms of OPl (e.g., OPl-16Ser, OPl-16Leu, OPl-16Met, OPl-16Ala and OPl-16Val). The protein was greater than 90% pure. The implants were immersed for 30 minutes in

200 μl 50% ethanol/0.01% TFA containing 5 μg recombinant protein and the solution frozen in an ethanol/dry ice bath while the formulation tube was rolled. The tubes were subsequently freeze dried. Nineteen implants were also prepared by treatment with ethanol/TFA without the OPl protein by the same procedure.

In test implants, it was found that OPl could be extracted from treated implants with 8M urea, 1% Tween 80, 50mM Tris, pH 8.0 and analyzed by HPLC. By this method, it was shown that all of the OPl in the formulation tubes bound to the implant under the conditions employed. Furthermore, since the test implants were half coated with HA, additional implants were obtained to independently evaluate the binding of OPl to each of these surfaces. Initial binding studies showed that the OPl binds more readily to the HA than to the uncoated metal.

The implants for the second study were evaluated in skeletally mature adult mongrel dogs using the femoral transcortical model. Standard aseptic surgical techniques were used such that each animal received five implants bilaterally. Implantation periods of three weeks were used. The mechanical and quantitative histological data are shown in Table III. Three HA-coated and uncoated configurations were evaluated: controls (no treatment), precoat samples (formulated without OPl) and the OPl samples.

TABLE III METAL IMPLANTS - OP-1

INTERFACE SHEAR ATTACHMENT STRENGTH, MPA PERCENT BONE INGROWTH

3 Weeks: 3 Weeks:

HA-coated Uncoated HA-coated Uncoated

Control 7.59+2.99 6.47+1.23 44.98+12.57 41.66+11.91 (n=10) (n=10) (n=24) (n=24)

Precoat 7.85+3.43 6.49+2.20 40.73+16.88 39.14+16.18 (n=9) (n=9) (n=24) (n=24)

Protein 8.69+3.17 6.34+3.04 48.68+16.61 47.89+11.91 (hOP-1) (n=17) (n=17) (n=24) (n=24)

Mechanical testing results demonstrated enhanced attachment strength for the HA-coated samples as compared to the uncoated samples. At three weeks the greatest fixation was observed with the HA-coated implant with protein.

Histologic analysis demonstrated greater bone ingrowth for all HA-coated versus uncoated samples although the differences were not significant. The percent bone ingrowth was greatest for the HA-coated and uncoated implants with the protein present. Linear regression analysis demonstrated that attachment strength was predicted by amount of bone growth into the porous structure, presence of HA coating, and presence of protein.

Example 2

Titanium frequently is used to fabricate metal prostheses. The surface of these prostheses comprise a layer of titanium oxide. Therefore, titanium oxide itself was evaluated for its ability to serve as a carrier for OP-1 and in general for its biocompatibility with the bone formation process. The _in vivo biological activity of implants containing a combination of titanium oxide and OP-1 (Sequence ID No. 1, residues 293-431)

was examined in rat subcutaneous and intramuscular assays. Implants contained 0, 6.25, 12.5, 25 or 50 μg of OP-1 formulated onto 30 mg of titanium oxide.

Implants were formulated by a modification of the ethanol/TFA freeze-drying method. Titanium oxide pellets were milled and sieved to a particle size of 250-420 microns. 30 mg of these particles were mixed with 50 μl aliquots of 45% ethanol, 0.09% trifluoroacetic acid containing no OP-1 or various concentrations of OP-1. After 3 hours at 4 °C, the samples were frozen, freeze-dried and implanted into rats.

After 12 days i-n vivo the implants were removed and evaluated for bone formation by alkaline phosphatase specific activity, calcium content and histological evidence. The results showed that OP-1 induced the formation of bone at each concentration of OP-1 at both the subcutaneous and intramuscular implant sites. No bone formed without OP-1 added to the titanium oxide. The amount of bone as quantitated by calcium content of the implants was similar to that observed using bone collagen carriers. Therefore titanium is a useful carrier for osteogenic proteins and is biocompatible with the bone formation process.

Example 3

The efficacy of the method of this invention on standard dental prosthesis may be assessed using the following model and protocol. Maxillary and mandibular incisor and mandibular canine teeth are extracted from several (e.g., 3) male cynomolgus (Macca fascularis) monkeys (4-6 kilograms) under ketamine anesthesia and local infiltration of lidocaine. Hemostasis is achieved with pressure.

The resultant toothless sockets are filled either with (a) collagen matrix (CM), (b) with collagen matrix containing osteogenic protein, such as the recombinantly produced OPl protein used in Example 1, above (e.g., an ostegenic device) or c) are left untreated. Titanium, self-tapping, oral.

endosseous implants (Nobelpharma, Chicago, 111.) are inserted into all of the sockets by minimally engaging the self-tapping tip. The mucoperiosteal flap is released from the underlying tissue and used to obtain primary wound closure using standard surgical procedures known in the medical art.

The animals are sacrificed after three weeks by lethal injection of pentobarbital and perfusion with paraformaldehyde-glutaraldehyde. The jaws then are dissected and the blocks containing the appropriate sockets are resected, further fixed in neutral buffered formalin, decalcified in formic acid and sodium citrate, embedded in plastic and stained with basic Fuchsin and toluidine blue. Sections then are analyzed by light microscopy. Preferably, computer assisted histomorphometric analysis is used to evaluate the new tissue, e.g., using Image 1.27 and Quick Capture ^R (Data Translation, Inc. Marlboro, MA 07152).

It is anticipated that sockets which contain the osteogenic device will induce the formation of new bone in close apposition to the threaded surface of the titanium implants within 3 weeks. By contrast, sockets treated only with collagen matrix or sockets receiving neither collagen matrix nor the osteogenic device should show no evidence of new bone formation in close apposition to the implant surface.

Equivalents

One skilled in the art will be able to ascertain, using no more than routine experimentation, many equivalents to the subject matter described herein. Such equivalents are intended to be encompassed by the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION: (i) APPLICANT:

(A NAME: Creative BioMolecules, Inc. (B STREET: 35 South Street (C CITY: Hopkinton (D STATE: Massachusetts (E COUNTRY: United States (F POSTAL CODE (ZIP): 01748 (G TELEPHONE: 1-508-435-9001 (H TELEFAX: 1-508-435-0454 (I TELEX:

(A NAME: Stryker Biotech (B STREET: One Apple Hill (C CITY: Natick (D. STATE: Massachusetts (E COUNTRY: United States (F POSTAL CODE (ZIP): 01760 (G TELEPHONE: 1-508-653-2280 (H TELEFAX: 1-508-653-2770 (I TELEX:

(ϋ) TITLE OF INVENTION: PROSTHETIC DEVICES HAVING ENHANCED OSTEOGENIC PROPERTIES

(iii) NUMBER OF SEQUENCES: 22

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Creative BioMolecules, Inc.

(B) STREET: 35 South Street

(C) CITY: Hopkinton

(D) STATE: MA

(E) COUNTRY: USA

(F) ZIP: 01748

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: PITCHER ESQ, EDMUND R

(B) REGISTRATION NUMBER: 27,829

(C) REFERENCE/DOCKET NUMBER: ST -057

(ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 617/248-7000

(2) INFORMATION FOR SEQ ID N0:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1822 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: HOMO SAPIENS (F) TISSUE TYPE: HIPPOCAMPUS

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 49..1341

(C) IDENTIFICATION METHOD: experimental

(D) OTHER INFORMATION: /function= "OSTEOGENIC PROTEIN"

/product= "OPl" /evidence= EXPERIMENTAL /standard name= "OPl"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l:

GGTGCGGGCC CGGAGCCCGG AGCCCGGGTA GCGCGTAGAG CCGGCGCG ATG CAC GTG 57

Met His Val 1

CGC TCA CTG CGA GCT GCG GCG CCG CAC AGC TTC GTG GCG CTC TGG GCA 105 Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala Leu Trp Ala 5 10 15

CCC CTG TTC CTG CTG CGC TCC GCC CTG GCC GAC TTC AGC CTG GAC AAC 153 Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser Leu Asp Asn 20 25 30 35

GAG GTG CAC TCG AGC TTC ATC CAC CGG CGC CTC CGC AGC CAG GAG CGG 201 Glu Val His Ser Ser Phe lie His Arg Arg Leu Arg Ser Gin Glu Arg 40 45 50

CGG GAG ATG CAG CGC GAG ATC CTC TCC ATT TTG GGC TTG CCC CAC CGC 249 Arg Glu Met Gin Arg Glu lie Leu Ser He Leu Gly Leu Pro His Arg 55 60 65

CCG CGC CCG CAC CTC CAG GGC AAG CAC AAC TCG GCA CCC ATG TTC ATG 297 Pro Arg Pro His Leu Gin Gly Lys His Asn Ser Ala Pro Met Phe Met 70 75 80

CTG GAC CTG TAC AAC GCC ATG GCG GTG GAG GAG GGC GGC GGG CCC GGC 345 Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Gly Gly Gly Pro Gly 85 90 95

GGC CAG GGC TTC TCC TAC CCC TAC AAG GCC GTC TTC AGT ACC CAG GGC 393 Gly Gin Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr Gin Gly 100 105 110 115

CCC CCT CTG GCC AGC CTG CAA GAT AGC CAT TTC CTC ACC GAC GCC GAC 441 Pro Pro Leu Ala Ser Leu Gin Asp Ser His Phe Leu Thr Asp Ala Asp 120 125 130

ATG GTC ATG AGC TTC GTC AAC CTC GTG GAA CAT GAC AAG GAA TTC TTC 489 Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu Phe Phe 135 140 145

CAC CCA CGC TAC CAC CAT CGA GAG TTC CGG TTT GAT CTT TCC AAG ATC 537 His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser Lys He 150 155 160

CCA GAA GGG GAA GCT GTC ACG GCA GCC GAA TTC CGG ATC TAC AAG GAC 585 Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg He Tyr Lys Asp 165 170 175

TAC ATC CGG GAA CGC TTC GAC AAT GAG ACG TTC CGG ATC AGC GTT TAT 633 Tyr He Arg Glu Arg Phe Asp Asn Glu Thr Phe Arg He Ser Val Tyr 180 185 190 195

CAG GTG CTC CAG GAG CAC TTG GGC AGG GAA TCG GAT CTC TTC CTG CTC 681 Gin Val Leu Gin Glu His Leu Gly Arg Glu Ser Asp Leu Phe Leu Leu 200 205 210

GAC AGC CGT ACC CTC TGG GCC TCG GAG GAG GGC TGG CTG GTG TTT GAC 729 Asp Ser Arg Thr Leu Trp Ala Ser Glu Glu Gly Trp Leu Val Phe Asp 215 220 225

ATC ACA GCC ACC AGC AAC CAC TGG GTG GTC AAT CCG CGG CAC AAC CTG 777 He Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His Asn Leu 230 235 240

GGC CTG CAG CTC TCG GTG GAG ACG CTG GAT GGG CAG AGC ATC AAC CCC 825 Gly Leu Gin Leu Ser Val Glu Thr Leu Asp Gly Gin Ser He Asn Pro 245 250 255

AAG TTG GCG GGC CTG ATT GGG CGG CAC GGG CCC CAG AAC AAG CAG CCC 873 Lys Leu Ala Gly Leu He Gly Arg His Gly Pro Gin Asn Lys Gin Pro 260 265 270 275

TTC ATG GTG GCT TTC TTC AAG GCC ACG GAG GTC CAC TTC CGC AGC ATC 921 Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Phe Arg Ser He 280 285 290

CGG TCC ACG GGG AGC AAA CAG CGC AGC CAG AAC CGC TCC AAG ACG CCC 969 Arg Ser Thr Gly Ser Lys Gin Arg Ser Gin Asn Arg Ser Lys Thr Pro 295 300 305

AAG AAC CAG GAA GCC CTG CGG ATG GCC AAC GTG GCA GAG AAC AGC AGC 1017 Lys Asn Gin Glu Ala Leu Arg Met Ala Asn Val Ala Glu Asn Ser Ser 310 315 320

AGC GAC CAG AGG CAG GCC TGT AAG AAG CAC GAG CTG TAT GTC AGC TTC 1065 Ser Asp Gin Arg Gin Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe 325 330 335

CGA GAC CTG GGC TGG CAG GAC TGG ATC ATC GCG CCT GAA GGC TAC GCC 1113 Arg Asp Leu Gly Trp Gin Asp Trp He He Ala Pro Glu Gly Tyr Ala 340 345 350 355

GCC TAC TAC TGT GAG GGG GAG TGT GCC TTC CCT CTG AAC TCC TAC ATG 1161 Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met 360 365 370

AAC GCC ACC AAC CAC GCC ATC GTG CAG ACG CTG GTC CAC TTC ATC AAC 1209 Asn Ala Thr Asn His Ala He Val Gin Thr Leu Val His Phe He Asn 375 380 385

CCG GAA ACG GTG CCC AAG CCC TGC TGT GCG CCC ACG CAG CTC AAT GCC 1257 Pro Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gin Leu Asn Ala 390 395 400

ATC TCC GTC CTC TAC TTC GAT GAC AGC TCC AAC GTC ATC CTG AAG AAA 1305 He Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val He Leu Lys Lys 405 410 415

TAC AGA AAC ATG GTG GTC CGG GCC TGT GGC TGC CAC TAGCTCCTCC 1351

Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His 420 425 430

GAGAATTCAG ACCCTTTGGG GCCAAGTTTT TCTGGATCCT CCATTGCTCG CCTTGGCCAG 1411

GAACCAGCAG ACCAACTGCC TTTTGTGAGA CCTTCCCCTC CCTATCCCCA ACTTTAAAGG 1471

TGTGAGAGTA TTAGGAAACA TGAGCAGCAT ATGGCTTTTG ATCAGTTTTT CAGTGGCAGC 1531

ATCCAATGAA CAAGATCCTA CAAGCTGTGC AGGCAAAACC TAGCAGGAAA AAAAAACAAC 1591

GCATAAAGAA AAATGGCCGG GCCAGGTCAT TGGCTGGGAA GTCTCAGCCA TGCACGGACT 1651

CGTTTCCAGA GGTAATTATG AGCGCCTACC AGCCAGGCCA CCCAGCCGTG GGAGGAAGGG 1711

GGCGTGGCAA GGGGTGGGCA CATTGGTGTC TGTGCGAAAG GAAAATTGAC CCGGAAGTTC 1771

CTGTAATAAA TGTCACAATA AAACGAATGA ATGAAAAAAA AAAAAAAAAA A 1822

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 431 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met His Val Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala 1 5 10 15

Leu Trp Ala Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser 20 25 30

Leu Asp Asn Glu Val His Ser Ser Phe He His Arg Arg Leu Arg Ser 35 40 45

Gin Glu Arg Arg Glu Met Gin Arg Glu He Leu Ser He Leu Gly Leu 50 55 60

Pro His Arg Pro Arg Pro His Leu Gin Gly Lys His Asn Ser Ala Pro 65 70 75 80

Met Phe Met Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Gly Gly 85 90 95

Gly Pro Gly Gly Gin Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser 100 105 110

Thr Gin Gly Pro Pro Leu Ala Ser Leu Gin Asp Ser His Phe Leu Thr 115 120 125

Asp Ala Asp Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys 130 135 140

Glu Phe Phe His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu 145 150 155 160

Ser Lys He Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg He 165 170 175

Tyr Lys Asp Tyr He Arg Glu Arg Phe Asp Asn Glu Thr Phe Arg He 180 185 190

Ser Val Tyr Gin Val Leu Gin Glu His Leu Gly Arg Glu Ser Asp Leu 195 200 205

Phe Leu Leu Asp Ser Arg Thr Leu Trp Ala Ser Glu Glu Gly Trp Leu 210 215 220

Val Phe Asp He Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg 225 230 235 240

His Asn Leu Gly Leu Gin Leu Ser Val Glu Thr Leu Asp Gly Gin Ser 245 250 255

He Asn Pro Lys Leu Ala Gly Leu He Gly Arg His Gly Pro Gin Asn 260 265 270

Lys Gin Pro Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Phe 275 280 285

Arg Ser He Arg Ser Thr Gly Ser Lys Gin Arg Ser Gin Asn Arg Ser 290 295 300

Lys Thr Pro Lys Asn Gin Glu Ala Leu Arg Met Ala Asn Val Ala Glu 305 310 315 320

Asn Ser Ser Ser Asp Gin Arg Gin Ala Cys Lys Lys His Glu Leu Tyr 325 330 335

Val Ser Phe Arg Asp Leu Gly Trp Gin Asp Trp He He Ala Pro Glu 340 345 350

Gly Tyr Ala Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn 355 360 365

Ser Tyr Met Asn Ala Thr Asn His Ala He Val Gin Thr Leu Val His 370 375 380

Phe He Asn Pro Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gin 385 390 395 400

Leu Asn Ala He Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val He 405 410 415

Leu Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His 420 425 430

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 96 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..96

(D) OTHER INFORMATION: /note= "C0P-5"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asp Asp Trp He Val Ala 1 5 10 15

Pro Pro Gly Tyr Gin Ala Phe Tyr Cys His Gly Glu Cys Pro Phe Pro 20 25 30

Leu Ala Asp His Phe Asn Ser Thr Asn His Ala Val Val Gin Thr Leu 35 40 45

Val Asn Ser Val Asn Ser Lys He Pro Lys Ala Cys Cys Val Pro Thr 50 55 60

Glu Leu Ser Ala He Ser Met Leu Tyr Leu Asp Glu Asn Glu Lys Val 65 70 75 80

Val Leu Lys Asn Tyr Gin Glu Met Val Val Glu Gly Cys Gly Cys Arg 85 90 95

(2) INFORMATION FOR SEQ ID NO: :

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 96 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..96

(D) OTHER INFORMATION: /note= "COP-7"

( i) SEQUENCE DESCRIPTION: SEQ ID NO: :

Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn Asp Trp He Val Ala 1 5 10 15

Pro Pro Gly Tyr His Ala Phe Tyr Cys His Gly Glu Cys Pro Phe Pro 20 25 30

Leu Ala Asp His Leu Asn Ser Thr Asn His Ala Val Val Gin Thr Leu

35 40 45

Val Asn Ser Val Asn Ser Lys He Pro Lys Ala Cys Cys Val Pro Thr 50 55 60

Glu Leu Ser Ala He Ser Met Leu Tyr Leu Asp Glu Asn Glu Lys Val 65 70 75 80

Val Leu Lys Asn Tyr Gin Glu Met Val Val Glu Gly Cys Gly Cys Arg 85 90 95

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 102 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(A) ORGANISM: DROSOPHILA MELANOGASTER

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..101

(D) OTHER INFORMATION: /label= DPP-FX

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Cys Arg Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asp 1 5 10 15

Asp Trp He Val Ala Pro Leu Gly Tyr Asp Ala Tyr Tyr Cys His Gly 20 25 30

Lys Cys Pro Phe Pro Leu Ala Asp His Phe Asn Ser Thr Asn His Ala 35 40 45

Val Val Gin Thr Leu Val Asn Asn Asn Asn Pro Gly Lys Val Pro Lys 50 55 60

Ala Cys Cys Val Pro Thr Gin Leu Asp Ser Val Ala Met Leu Tyr Leu 65 70 75 80

Asn Asp Gin Ser Thr Val Val Leu Lys Asn Tyr Gin Glu Met Thr Val 85 90 95

Val Gly Cys Gly Cys Arg 100

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 102 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(A) ORGANISM: XENOPUS

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..102

(D) OTHER INFORMATION: /label- VG1-FX

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Cys Lys Lys Arg His Leu Tyr Val Glu Phe Lys Asp Val Gly Trp Gin 1 5 10 15

Asn Trp Val He Ala Pro Gin Gly Tyr Met Ala Asn Tyr Cys Tyr Gly 20 25 30

Glu Cys Pro Tyr Pro Leu Thr Glu He Leu Asn Gly Ser Asn His Ala 35 40 45

He Leu Gin Thr Leu Val His Ser He Glu Pro Glu Asp He Pro Leu 50 55 60

Pro Cys Cys Val Pro Thr Lys Met Ser Pro He Ser Met Leu Phe Tyr 65 70 75 80

Asp Asn Asn Asp Asn Val Val Leu Arg His Tyr Glu Asn Met Ala Val 85 90 95

Asp Glu Cys Gly Cys Arg 100

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 102 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(A) ORGANISM: MURIDAE

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..102

(D) OTHER INFORMATION: /label= VGR-l-FX

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Cys Lys Lys His Gly Leu Tyr Val Ser Phe Gin Asp Val Gly Trp Gin 1 5 10 15

Asp Trp He He Ala Pro Xaa Gly Tyr Ala Ala Asn Tyr Cys Asp Gly 20 25 30

Glu Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala 35 40 45

He Val Gin Thr Leu Val His Val Met Asn Pro Glu Tyr Val Pro Lys 50 55 60

Pro Cys Cys Ala Pro Thr Lys Val Asn Ala He Ser Val Leu Tyr Phe 65 70 75 80

Asp Asp Asn Ser Asn Val He Leu Lys Lys Tyr Arg Asn Met Val Val 85 90 95

Arg Ala Cys Gly Cys His 100

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1873 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: MURIDAE (F) TISSUE TYPE: EMBRYO

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 104..1393

(D) OTHER INFORMATION: /function--- "OSTEOGENIC PROTEIN" /product- "MOPl" /note= "MOPl (CDNA)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CTGCAGCAAG TGACCTCGGG TCGTGGACCG CTGCCCTGCC CCCTCCGCTG CCACCTGGGG 60

CGGCGCGGGC CCGGTGCCCC GGATCGCGCG TAGAGCCGGC GCG ATG CAC GTG CGC 115

Met His Val Arg 1

TCG CTG CGC GCT GCG GCG CCA CAC AGC TTC GTG GCG CTC TGG GCG CCT 163 Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala Leu Trp Ala Pro 5 10 15 20

CTG TTC TTG CTG CGC TCC GCC CTG GCC GAT TTC AGC CTG GAC AAC GAG 211 Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser Leu Asp Asn Glu 25 30 35

GTG CAC TCC AGC TTC ATC CAC CGG CGC CTC CGC AGC CAG GAG CGG CGG 259 Val His Ser Ser Phe He His Arg Arg Leu Arg Ser Gin Glu Arg Arg 40 45 50

GAG ATG CAG CGG GAG ATC CTG TCC ATC TTA GGG TTG CCC CAT CGC CCG 307 Glu Met Gin Arg Glu He Leu Ser He Leu Gly Leu Pro His Arg Pro 55 60 65

CGC CCG CAC CTC CAG GGA AAG CAT AAT TCG GCG CCC ATG TTC ATG TTG 355 Arg Pro His Leu Gin Gly Lys His Asn Ser Ala Pro Met Phe Met Leu 70 75 80

GAC CTG TAC AAC GCC ATG GCG GTG GAG GAG AGC GGG CCG GAC GGA CAG 403 Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Ser Gly Pro Asp Gly Gin 85 90 95 100

GGC TTC TCC TAC CCC TAC AAG GCC GTC TTC AGT ACC CAG GGC CCC CCT 451 Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr Gin Gly Pro Pro 105 110 115

TTA GCC AGC CTG CAG GAC AGC CAT TTC CTC ACT GAC GCC GAC ATG GTC 499 Leu Ala Ser Leu Gin Asp Ser His Phe Leu Thr Asp Ala Asp Met Val 120 125 130

ATG AGC TTC GTC AAC CTA GTG GAA CAT GAC AAA GAA TTC TTC CAC CCT 547 Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu Phe Phe His Pro 135 140 145

CGA TAC CAC CAT CGG GAG TTC CGG TTT GAT CTT TCC AAG ATC CCC GAG 595 Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser Lys He Pro Glu 150 155 160

GGC GAA CGG GTG ACC GCA GCC GAA TTC AGG ATC TAT AAG GAC TAC ATC 643 Gly Glu Arg Val Thr Ala Ala Glu Phe Arg He Tyr Lys Asp Tyr He 165 170 175 180

CGG GAG CGA TTT GAC AAC GAG ACC TTC CAG ATC ACA GTC TAT CAG GTG 691 Arg Glu Arg Phe Asp Asn Glu Thr Phe Gin He Thr Val Tyr Gin Val 185 190 195

CTC CAG GAG CAC TCA GGC AGG GAG TCG GAC CTC TTC TTG CTG GAC AGC 739 Leu Gin Glu His Ser Gly Arg Glu Ser Asp Leu Phe Leu Leu Asp Ser 200 205 210

CGC ACC ATC TGG GCT TCT GAG GAG GGC TGG TTG GTG TTT GAT ATC ACA 787 Arg Thr He Trp Ala Ser Glu Glu Gly Trp Leu Val Phe Asp He Thr 215 220 225

GCC ACC AGC AAC CAC TGG GTG GTC AAC CCT CGG CAC AAC CTG GGC TTA 835 Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His Asn Leu Gly Leu 230 235 240

CAG CTC TCT GTG GAG ACC CTG GAT GGG CAG AGC ATC AAC CCC AAG TTG 883

Gin Leu Ser Val Glu Thr Leu Asp Gly Gin Ser He Asn Pro Lys Leu 245 250 255 260

GCA GGC CTG ATT GGA CGG CAT GGA CCC CAG AAC AAG CAA CCC TTC ATG 931

Ala Gly Leu He Gly Arg His Gly Pro Gin Asn Lys Gin Pro Phe Met

265 270 275

GTG GCC TTC TTC AAG GCC ACG GAA GTC CAT CTC CGT AGT ATC CGG TCC 979

Val Ala Phe Phe Lys Ala Thr Glu Val His Leu Arg Ser He Arg Ser 280 285 290

ACG GGG GGC AAG CAG CGC AGC CAG AAT CGC TCC AAG ACG CCA AAG AAC 1027 Thr Gly Gly Lys Gin Arg Ser Gin Asn Arg Ser Lys Thr Pro Lys Asn 295 300 305

CAA GAG GCC CTG AGG ATG GCC AGT GTG GCA GAA AAC AGC AGC AGT GAC 1075 Gin Glu Ala Leu Arg Met Ala Ser Val Ala Glu Asn Ser Ser Ser Asp 310 315 320

CAG AGG CAG GCC TGC AAG AAA CAT GAG CTG TAC GTC AGC TTC CGA GAC 1123 Gin Arg Gin Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg Asp 325 330 335 340

CTT GGC TGG CAG GAC TGG ATC ATT GCA CCT GAA GGC TAT GCT GCC TAC 1171 Leu Gly Trp Gin Asp Trp He He Ala Pro Glu Gly Tyr Ala Ala Tyr 345 350 355

TAC TGT GAG GGA GAG TGC GCC TTC CCT CTG AAC TCC TAC ATG AAC GCC 1219 Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met Asn Ala 360 365 370

ACC AAC CAC GCC ATC GTC CAG ACA CTG GTT CAC TTC ATC AAC CCA GAC 1267 Thr Asn His Ala He Val Gin Thr Leu Val His Phe He Asn Pro Asp 375 380 385

ACA GTA CCC AAG CCC TGC TGT GCG CCC ACC CAG CTC AAC GCC ATC TCT 1315 Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gin Leu Asn Ala He Ser 390 395 400

GTC CTC TAC TTC GAC GAC AGC TCT AAT GTC GAC CTG AAG AAG TAC AGA 1363 Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Asp Leu Lys Lys Tyr Arg 405 410 415 420

AAC ATG GTG GTC CGG GCC TGT GGC TGC CAC TAGCTCTTCC TGAGACCCTG 1413 Asn Met Val Val Arg Ala Cys Gly Cys His 425 430

ACCTTTGCGG GGCCACACCT TTCCAAATCT TCGATGTCTC ACCATCTAAG TCTCTCACTG 1473

CCCACCTTGG CGAGGAGAAC AGACCAACCT CTCCTGAGCC TTCCCTCACC TCCCAACCGG 1533

AAGCATGTAA GGGTTCCAGA AACCTGAGCG TGCAGCAGCT GATGAGCGCC CTTTCCTTCT 1593

GGCACGTGAC GGACAAGATC CTACCAGCTA CCACAGCAAA CGCCTAAGAG CAGGAAAAAT 1653

GTCTGCCAGG AAAGTGTCCA GTGTCCACAT GGCCCCTGGC GCTCTGAGTC TTTGAGGAGT 1713

AATCGCAAGC CTCGTTCAGC TGCAGCAGAA GGAAGGGCTT AGCCAGGGTG GGCGCTGGCG 1773

TCTGTGTTGA AGGGAAACCA AGCAGAAGCC ACTGTAATGA TATGTCACAA TAAAACCCAT 1833

GAATGAAAAA AAAAAAAAAA AAAAAAAAAA AAAAGAATTC 1873

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 430 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

( i) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Met His Val Arg Ser LeU Arg Ala Ala Ala Pro His Ser Phe Val Ala 1 5 10 15

Leu Trp Ala Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser 20 25 30

Leu Asp Asn Glu Val His Ser Ser Phe He His Arg Arg Leu Arg Ser 35 40 45

Gin Glu Arg Arg Glu Met Gin Arg Glu He Leu Ser He Leu Gly Leu 50 55 60

Pro His Arg Pro Arg Pro His Leu Gin Gly Lys His Asn Ser Ala Pro 65 70 75 80

Met Phe Met Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Ser Gly 85 90 95

Pro Asp Gly Gin Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr 100 105 110

Gin Gly Pro Pro Leu Ala Ser Leu Gin Asp Ser His Phe Leu Thr Asp 115 120 125

Ala Asp Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu 130 135 140

Phe Phe His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser 145 150 155 160

Lys He Pro Glu Gly Glu Arg Val Thr Ala Ala Glu Phe Arg He Tyr 165 170 175

Lys Asp Tyr He Arg Glu Arg Phe Asp Asn Glu Thr Phe Gin He Thr 180 185 190

Val Tyr Gin Val Leu Gin Glu His Ser Gly Arg Glu Ser Asp Leu Phe 195 200 205

Leu Leu Asp Ser Arg Thr He Trp Ala Ser Glu Glu Gly Trp Leu Val 210 215 220

Phe Asp He Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His 225 230 235 240

Asn Leu Gly Leu Gin Leu Ser Val Glu Thr Leu Asp Gly Gin Ser He 245 250 255

Asn Pro Lys Leu Ala Gly Leu He Gly Arg His Gly Pro Gin Asn Lys 260 265 270

Gin Pro Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Leu Arg 275 280 285

Ser He Arg Ser Thr Gly Gly Lys Gin Arg Ser Gin Asn Arg Ser Lys 290 295 300

Thr Pro Lys Asn Gin Glu Ala Leu Arg Met Ala Ser Val Ala Glu Asn 305 310 315 320

Ser Ser Ser Asp Gin Arg Gin Ala Cys Lys Lys His Glu Leu Tyr Val 325 330 335

Ser Phe Arg Asp Leu Gly Trp Gin Asp Trp He He Ala Pro Glu Gly 340 345 350

Tyr Ala Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser 355 360 365

Tyr Met Asn Ala Thr Asn His Ala He Val Gin Thr Leu Val His Phe 370 375 380

He Asn Pro Asp Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gin Leu 385 390 395 400

Asn Ala He Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Asp Leu 405 410 415

Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His 420 425 430

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1723 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens (F) TISSUE TYPE: HIPPOCAMPUS

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 490..1696

(D) OTHER INFORMATION: /function= "OSTEOGENIC PROTEIN" /product- "hOP2-PP" /note- "hOP2 (cDNA)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GGCGCCGGCA GAGCAGGAGT GGCTGGAGGA GCTGTGGTTG GAGCAGGAGG TGGCACGGCA 60

GGGCTGGAGG GCTCCCTATG AGTGGCGGAG ACGGCCCAGG AGGCGCTGGA GCAACAGCTC 120

CCACACCGCA CCAAGCGGTG GCTGCAGGAG CTCGCCCATC GCCCCTGCGC TGCTCGGACC 180

GCGGCCACAG CCGGACTGGC GGGTACGGCG GCGACAGAGG CATTGGCCGA GAGTCCCAGT 240

CCGCAGAGTA GCCCCGGCCT CGAGGCGGTG GCGTCCCGGT CCTCTCCGTC CAGGAGCCAG 300

GACAGGTGTC GCGCGGCGGG GCTCCAGGGA CCGCGCCTGA GGCCGGCTGC CCGCCCGTCC 360

CGCCCCGCCC CGCCGCCCGC CGCCCGCCGA GCCCAGCCTC CTTGCCGTCG GGGCGTCCCC 420

AGGCCCTGGG TCGGCCGCGG AGCCGATGCG CGCCCGCTGA GCGCCCCAGC TGAGCGCCCC 480

CGGCCTGCC ATG ACC GCG CTC CCC GGC CCG CTC TGG CTC CTG GGC CTG 528 Met Thr Ala Leu Pro Gly Pro Leu Trp Leu Leu Gly Leu 1 5 10

GCG CTA TGC GCG CTG GGC GGG GGC GGC CCC GGC CTG CGA CCC CCG CCC 576 Ala Leu Cys Ala Leu Gly Gly Gly Gly Pro Gly Leu Arg Pro Pro Pro 15 20 25

GGC TGT CCC CAG CGA CGT CTG GGC GCG CGC GAG CGC CGG GAC GTG CAG 624 Gly Cys Pro Gin Arg Arg Leu Gly Ala Arg Glu Arg Arg Asp Val Gin 30 35 40 45

CGC GAG ATC CTG GCG GTG CTC GGG CTG CCT GGG CGG CCC CGG CCC CGC 672 Arg Glu He Leu Ala Val Leu Gly Leu Pro Gly Arg Pro Arg Pro Arg 50 55 60

GCG CCA CCC GCC GCC TCC CGG CTG CCC GCG TCC GCG CCG CTC TTC ATG 720 Ala Pro Pro Ala Ala Ser Arg Leu Pro Ala Ser Ala Pro Leu Phe Met 65 70 75

CTG GAC CTG TAC CAC GCC ATG GCC GGC GAC GAC GAC GAG GAC GGC GCG 768 Leu Asp Leu Tyr His Ala Met Ala Gly Asp Asp Asp Glu Asp Gly Ala 80 85 90

CCC GCG GAG CGG CGC CTG GGC CGC GCC GAC CTG GTC ATG AGC TTC GTT 816 Pro Ala Glu Arg Arg Leu Gly Arg Ala Asp Leu Val Met Ser Phe Val 95 100 105

AAC ATG GTG GAG CGA GAC CGT GCC CTG GGC CAC CAG GAG CCC CAT TGG 864 Asn Met Val Glu Arg Asp Arg Ala Leu Gly His Gin Glu Pro His Trp 110 115 120 125

AAG GAG TTC CGC TTT GAC CTG ACC CAG ATC CCG GCT GGG GAG GCG GTC 912 Lys Glu Phe Arg Phe Asp Leu Thr Gin He Pro Ala Gly Glu Ala Val 130 135 140

ACA GCT GCG GAG TTC CGG ATT TAC AAG GTG CCC AGC ATC CAC CTG CTC 960 Thr Ala Ala Glu Phe Arg He Tyr Lys Val Pro Ser He His Leu Leu 145 150 155

AAC AGG ACC CTC CAC GTC AGC ATG TTC CAG GTG GTC CAG GAG CAG TCC 1008 Asn Arg Thr Leu His Val Ser Met Phe Gin Val Val Gin Glu Gin Ser 160 165 170

AAC AGG GAG TCT GAC TTG TTC TTT TTG GAT CTT CAG ACG CTC CGA GCT 1056 Asn Arg Glu Ser Asp Leu Phe Phe Leu Asp Leu Gin Thr Leu Arg Ala 175 180 185

GGA GAC GAG GGC TGG CTG GTG CTG GAT GTC ACA GCA GCC AGT GAC TGC 1104 Gly Asp Glu Gly Trp Leu Val Leu Asp Val Thr Ala Ala Ser Asp Cys 190 195 200 205

TGG TTG CTG AAG CGT CAC AAG GAC CTG GGA CTC CGC CTC TAT GTG GAG 1152 Trp Leu Leu Lys Arg His Lys Asp Leu Gly Leu Arg Leu Tyr Val Glu 210 215 220

ACT GAG GAC GGG CAC AGC GTG GAT CCT GGC CTG GCC GGC CTG CTG GGT 1200 Thr Glu Asp Gly His Ser Val Asp Pro Gly Leu Ala Gly Leu Leu Gly 225 230 235

CAA CGG GCC CCA CGC TCC CAA CAG CCT TTC GTG GTC ACT TTC TTC AGG 1248 Gin Arg Ala Pro Arg Ser Gin Gin Pro Phe Val Val Thr Phe Phe Arg 240 245 250

GCC AGT CCG AGT CCC ATC CGC ACC CCT CGG GCA GTG AGG CCA CTG AGG 1296 Ala Ser Pro Ser Pro He Arg Thr Pro Arg Ala Val Arg Pro Leu Arg 255 260 265

AGG AGG CAG CCG AAG AAA AGC AAC GAG CTG CCG CAG GCC AAC CGA CTC 1344 Arg Arg Gin Pro Lys Lys Ser Asn Glu Leu Pro Gin Ala Asn Arg Leu 270 275 280 285

CCA GGG ATC TTT GAT GAC GTC CAC GGC TCC CAC GGC CGG CAG GTC TGC 1392 Pro Gly He Phe Asp Asp Val His Gly Ser His Gly Arg Gin Val Cys 290 295 300

CGT CGG CAC GAG CTC TAC GTC AGC TTC CAG GAC CTC GGC TGG CTG GAC 1440 Arg Arg His Glu Leu Tyr Val Ser Phe Gin Asp Leu Gly Trp Leu Asp 305 310 315

TGG GTC ATC GCT CCC CAA GGC TAC TCG GCC TAT TAC TGT GAG GGG GAG 1488 Trp Val He Ala Pro Gin Gly Tyr Ser Ala Tyr Tyr Cys Glu Gly Glu 320 325 330

TGC TCC TTC CCA CTG GAC TCC TGC ATG AAT GCC ACC AAC CAC GCC ATC 1536 Cys Ser Phe Pro Leu Asp Ser Cys Met Asn Ala Thr Asn His Ala He 335 340 345

CTG CAG TCC CTG GTG CAC CTG ATG AAG CCA AAC GCA GTC CCC AAG GCG 1584 Leu Gin Ser Leu Val His Leu Met Lys Pro Asn Ala Val Pro Lys Ala 350 355 360 365

TGC TGT GCA CCC ACC AAG CTG AGC GCC ACC TCT GTG CTC TAC TAT GAC 1632 Cys Cys Ala Pro Thr Lys Leu Ser Ala Thr Ser Val Leu Tyr Tyr Asp 370 375 380

AGC AGC AAC AAC GTC ATC CTG CGC AAA GCC CGC AAC ATG GTG GTC AAG 1680 Ser Ser Asn Asn Val He Leu Arg Lys Ala Arg Asn Met Val Val Lys 385 390 395

GCC TGC GGC TGC CAC T GAGTCAGCCC GCCCAGCCCT ACTGCAG 1723

Ala Cys Gly Cys His 400

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 402 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

( i) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Met Thr Ala Leu Pro Gly Pro Leu Trp Leu Leu Gly Leu Ala Leu Cys 1 5 10 15

Ala Leu Gly Gly Gly Gly Pro Gly Leu Arg Pro Pro Pro Gly Cys Pro 20 25 30

Gin Arg Arg Leu Gly Ala Arg Glu Arg Arg Asp Val Gin Arg Glu He 35 40 45

Leu Ala Val Leu Gly Leu Pro Gly Arg Pro Arg Pro Arg Ala Pro Pro 50 55 60

Ala Ala Ser Arg Leu Pro Ala Ser Ala Pro Leu Phe Met Leu Asp Leu 65 70 75 80

Tyr His Ala Met Ala Gly Asp Asp Asp Glu Asp Gly Ala Pro Ala Glu 85 90 95

Arg Arg Leu Gly Arg Ala Asp Leu Val Met Ser Phe Val Asn Met Val 100 105 110

Glu Arg Asp Arg Ala Leu Gly His Gin Glu Pro His Trp Lys Glu Phe 115 120 125

Arg Phe Asp Leu Thr Gin He Pro Ala Gly Glu Ala Val Thr Ala Ala 130 135 140

Glu Phe Arg He Tyr Lys Val Pro Ser He His Leu Leu Asn Arg Thr 145 150 155 160

Leu His Val Ser Met Phe Gin Val Val Gin Glu Gin Ser Asn Arg Glu 165 170 175

Ser Asp Leu Phe Phe Leu Asp Leu Gin Thr Leu Arg Ala Gly Asp Glu 180 185 190

Val Leu Asp Val Thr Ala Ala Ser Asp Cys Trp Leu Leu 200 205

Lys Asp Leu Gly Leu Arg Leu Tyr Val Glu Thr Glu Asp 215 220

Val Asp Pro Gly Leu Ala Gly Leu Leu Gly Gin Arg Ala 230 235 240

Gin Gin Pro Phe Val Val Thr Phe Phe Arg Ala Ser Pro 245 250 255

Arg Thr Pro Arg Ala Val Arg Pro Leu Arg Arg Arg Gin 260 265 270

Ser Asn Glu Leu Pro Gin Ala Asn Arg Leu Pro Gly He 280 285

Val His Gly Ser His Gly Arg Gin Val Cys Arg Arg His 295 300

Val Ser Phe Gin Asp Leu Gly Trp Leu Asp Trp Val He 310 315 320

Gly Tyr Ser Ala Tyr Tyr Cys Glu Gly Glu Cys Ser Phe 325 330 335

Ser Cys Met Asn Ala Thr Asn His Ala He Leu Gin Ser 340 345 350

Leu Met Lys Pro Asn Ala Val Pro Lys Ala Cys Cys Ala 360 365

Leu Ser Ala Thr Ser Val Leu Tyr Tyr Asp Ser Ser Asn 375 380

Leu Arg Lys Ala Arg Asn Met Val Val Lys Ala Cys Gly 390 395 400

Cys His

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1926 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(vi) ORIGINAL SOURCE:

(A) ORGANISM: MURIDAE (F) TISSUE TYPE: EMBRYO

( ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 93..1289

(D) OTHER INFORMATION: /function- "OSTEOGENIC PROTEIN" /product- "mOP2-PP" /note- "mOP2 cDNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GCCAGGCACA GGTGCGCCGT CTGGTCCTCC CCGTCTGGCG TCAGCCGAGC CCGACCAGCT 60

ACCAGTGGAT GCGCGCCGGC TGAAAGTCCG AG ATG GCT ATG CGT CCC GGG CCA 113

Met Ala Met Arg Pro Gly Pro 1 5

CTC TGG CTA TTG GGC CTT GCT CTG TGC GCG CTG GGA GGC GGC CAC GGT 161 Leu Trp Leu Leu Gly Leu Ala Leu Cys Ala Leu Gly Gly Gly His Gly 10 15 20

CCG CGT CCC CCG CAC ACC TGT CCC CAG CGT CGC CTG GGA GCG CGC GAG 209 Pro Arg Pro Pro His Thr Cys Pro Gin Arg Arg Leu Gly Ala Arg Glu 25 30 35

CGC CGC GAC ATG CAG CGT GAA ATC CTG GCG GTG CTC GGG CTA CCG GGA 257 Arg Arg Asp Met Gin Arg Glu He Leu Ala Val Leu Gly Leu Pro Gly 40 45 50 55

CGG CCC CGA CCC CGT GCA CAA CCC GCC GCT GCC CGG CAG CCA GCG TCC 305 Arg Pro Arg Pro Arg Ala Gin Pro Ala Ala Ala Arg Gin Pro Ala Ser 60 65 70

GCG CCC CTC TTC ATG TTG GAC CTA TAC CAC GCC ATG ACC GAT GAC GAC 353 Ala Pro Leu Phe Met Leu Asp Leu Tyr His Ala Met Thr Asp Asp Asp 75 80 85

GAC GGC GGG CCA CCA CAG GCT CAC TTA GGC CGT GCC GAC CTG GTC ATG 401 Asp Gly Gly Pro Pro Gin Ala His Leu Gly Arg Ala Asp Leu Val Met 90 95 100

AGC TTC GTC AAC ATG GTG GAA CGC GAC CGT ACC CTG GGC TAC CAG GAG 449 Ser Phe Val Asn Met Val Glu Arg Asp Arg Thr Leu Gly Tyr Gin Glu 105 110 115

CCA CAC TGG AAG GAA TTC CAC TTT GAC CTA ACC CAG ATC CCT GCT GGG 497 Pro His Trp Lys Glu Phe His Phe Asp Leu Thr Gin He Pro Ala Gly 120 125 130 135

GAG GCT GTC ACA GCT GCT GAG TTC CGG ATC TAC AAA GAA CCC AGC ACC 545 Glu Ala Val Thr Ala Ala Glu Phe Arg He Tyr Lys Glu Pro Ser Thr 140 145 150

CAC CCG CTC AAC ACA ACC CTC CAC ATC AGC ATG TTC GAA GTG GTC CAA 593 His Pro Leu Asn Thr Thr Leu His He Ser Met Phe Glu Val Val Gin 155 160 165

GAG CAC TCC AAC AGG GAG TCT GAC TTG TTC TTT TTG GAT CTT CAG ACG 641 Glu His Ser Asn Arg Glu Ser Asp Leu Phe Phe Leu Asp Leu Gin Thr 170 175 180

CTC CGA TCT GGG GAC GAG GGC TGG CTG GTG CTG GAC ATC ACA GCA GCC 689 Leu Arg Ser Gly Asp Glu Gly Trp Leu Val Leu Asp He Thr Ala Ala 185 190 195

AGT GAC CGA TGG CTG CTG AAC CAT CAC AAG GAC CTG GGA CTC CGC CTC 737 Ser Asp Arg Trp Leu Leu Asn His His Lys Asp Leu Gly Leu Arg Leu 200 205 210 215

TAT GTG GAA ACC GCG GAT GGG CAC AGC ATG GAT CCT GGC CTG GCT GGT 785 Tyr Val Glu Thr Ala Asp Gly His Ser Met Asp Pro Gly Leu Ala Gly 220 225 230

CTG CTT GGA CGA CAA GCA CCA CGC TCC AGA CAG CCT TTC ATG GTA ACC 833 Leu Leu Gly Arg Gin Ala Pro Arg Ser Arg Gin Pro Phe Met Val Thr 235 240 245

TTC TTC AGG GCC AGC CAG AGT CCT GTG CGG GCC CCT CGG GCA GCG AGA 881 Phe Phe Arg Ala Ser Gin Ser Pro Val Arg Ala Pro Arg Ala Ala Arg 250 255 260

CCA CTG AAG AGG AGG CAG CCA AAG AAA ACG AAC GAG CTT CCG CAC CCC 929 Pro Leu Lys Arg Arg Gin Pro Lys Lys Thr Asn Glu Leu Pro His Pro 265 270 275

AAC AAA CTC CCA GGG ATC TTT GAT GAT GGC CAC GGT TCC CGC GGC AGA 977 Asn Lys Leu Pro Gly He Phe Asp Asp Gly His Gly Ser Arg Gly Arg 280 285 290 295

GAG GTT TGC CGC AGG CAT GAG CTC TAC GTC AGC TTC CGT GAC CTT GGC 1025 Glu Val Cys Arg Arg His Glu Leu Tyr Val Ser Phe Arg Asp Leu Gly 300 305 310

TGG CTG GAC TGG GTC ATC GCC CCC CAG GGC TAC TCT GCC TAT TAC TGT 1073 Trp Leu Asp Trp Val He Ala Pro Gin Gly Tyr Ser Ala Tyr Tyr Cys 315 320 325

GAG GGG GAG TGT GCT TTC CCA CTG GAC TCC TGT ATG AAC GCC ACC AAC 1121 Glu Gly Glu Cys Ala Phe Pro Leu Asp Ser Cys Met Asn Ala Thr Asn 330 335 340

CAT GCC ATC TTG CAG TCT CTG GTG CAC CTG ATG AAG CCA GAT GTT GTC 1169 His Ala He Leu Gin Ser Leu Val His Leu Met Lys Pro Asp Val Val 345 350 355

CCC AAG GCA TGC TGT GCA CCC ACC AAA CTG AGT GCC ACC TCT GTG CTG 1217 Pro Lys Ala Cys Cys Ala Pro Thr Lys Leu Ser Ala Thr Ser Val Leu 360 365 370 375

TAC TAT GAC AGC AGC AAC AAT GTC ATC CTG CGT AAA CAC CGT AAC ATG 1265 Tyr Tyr Asp Ser Ser Asn Asn Val He Leu Arg Lys His Arg Asn Met 380 385 390

GTG GTC AAG GCC TGT GGC TGC CAC TGAGGCCCCG CCCAGCATCC TGCTTCTACT 1319 Val Val Lys Ala Cys Gly Cys His 395

ACCTTACCAT CTGGCCGGGC CCCTCTCCAG AGGCAGAAAC CCTTCTATGT TATCATAGCT 1379

CAGACAGGGG CAATGGGAGG CCCTTCACTT CCCCTGGCCA CTTCCTGCTA AAATTCTGGT 1439

CTTTCCCAGT TCCTCTGTCC TTCATGGGGT TTCGGGGCTA TCACCCCGCC CTCTCCATCC 1499

TCCTACCCCA AGCATAGACT GAATGCACAC AGCATCCCAG AGCTATGCTA ACTGAGAGGT 1559

CTGGGGTCAG CACTGAAGGC CCACATGAGG AAGACTGATC CTTGGCCATC CTCAGCCCAC 1619

AATGGCAAAT TCTGGATGGT CTAAGAAGGC CCTGGAATTC TAAACTAGAT GATCTGGGCT 1679

CTCTGCACCA TTCATTGTGG CAGTTGGGAC ATTTTTAGGT ATAACAGACA CATACACTTA 1739

GATCAATGCA TCGCTGTACT CCTTGAAATC AGAGCTAGCT TGTTAGAAAA AGAATCAGAG 1799

CCAGGTATAG CGGTGCATGT CATTAATCCC AGCGCTAAAG AGACAGAGAC AGGAGAATCT 1859

CTGTGAGTTC AAGGCCACAT AGAAAGAGCC TGTCTCGGGA GCAGGAAAAA AAAAAAAAAC 1919

GGAATTC 1926

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 399 amino acids

(B) TYPE: . amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

( i) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Met Ala Met Arg Pro Gly Pro Leu Trp Leu Leu Gly Leu Ala Leu Cys 1 5 10 15

Ala Leu Gly Gly Gly His Gly Pro Arg Pro Pro His Thr Cys Pro Gin 20 25 30

Gly Tyr Ser Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asp 325 330 335

Ser Cys Met Asn Ala Thr Asn His Ala He Leu Gin Ser Leu Val His 340 345 350

Leu Met Lys Pro Asp Val Val Pro Lys Ala Cys Cys Ala Pro Thr Lys 355 360 365

Leu Ser Ala Thr Ser Val Leu Tyr Tyr Asp Ser Ser Asn Asn Val He 370 375 380

Leu Arg Lys His Arg Asn Met Val Val Lys Ala Cys Gly Cys His 385 390 395

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1260 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(Vi) ORIGINAL SOURCE:

(A) ORGANISM: HOMO SAPIENS

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 9..1196

(D) OTHER INFORMATION: /function--- "OSTEOGENIC PROTEIN" /product- "BMP2A" ./note- "BMP2A (CDNA)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GGTCGACC ATG GTG GCC GGG ACC CGC TGT CTT CTA GCG TTG CTG CTT CCC 50 Met Val Ala Gly Thr Arg Cys Leu Leu Ala Leu Leu Leu Pro 1 5 10

CAG GTC CTC CTG GGC GGC GCG GCT GGC CTC GTT CCG GAG CTG GGC CGC 98 Gin Val Leu Leu Gly Gly Ala Ala Gly Leu Val Pro Glu Leu Gly Arg 15 20 25 30

AGG AAG TTC GCG GCG GCG TCG TCG GGC CGC CCC TCA TCC CAG CCC TCT 146 Arg Lys Phe Ala Ala Ala Ser Ser Gly Arg Pro Ser Ser Gin Pro Ser 35 40 45

GAC GAG GTC CTG AGC GAG TTC GAG TTG CGG CTG CTC AGC ATG TTC GGC 194 Asp Glu Val Leu Ser Glu Phe Glu Leu Arg Leu Leu Ser Met Phe Gly 50 55 60

CTG AAA CAG AGA CCC ACC CCC AGC AGG GAC GCC GTG GTG CCC CCC TAC 242 Leu Lys Gin Arg Pro Thr Pro Ser Arg Asp Ala Val Val Pro Pro Tyr 65 70 75

ATG CTA GAC CTG TAT CGC AGG CAC TCG GGT CAG CCG GGC TCA CCC GCC 290 Met Leu Asp Leu Tyr Arg Arg His Ser Gly Gin Pro Gly Ser Pro Ala 80 85 90

CCA GAC CAC CGG TTG GAG AGG GCA GCC AGC CGA GCC AAC ACT GTG CGC 338 Pro Asp His Arg Leu Glu Arg Ala Ala Ser Arg Ala Asn Thr Val Arg 95 100 105 110

AGC TTC CAC CAT GAA GAA TCT TTG GAA GAA CTA CCA GAA ACG AGT GGG 386 Ser Phe His His Glu Glu Ser Leu Glu Glu Leu Pro Glu Thr Ser Gly 115 120 125

AAA ACA ACC CGG AGA TTC TTC TTT AAT TTA AGT TCT ATC CCC ACG GAG 434 Lys Thr Thr Arg Arg Phe Phe Phe Asn Leu Ser Ser He Pro Thr Glu 130 135 140

GAG TTT ATC ACC TCA GCA GAG CTT CAG GTT TTC CGA GAA CAG ATG CAA 482 Glu Phe He Thr Ser Ala Glu Leu Gin Val Phe Arg Glu Gin Met Gin 145 150 155

GAT GCT TTA GGA AAC AAT AGC AGT TTC CAT CAC CGA ATT AAT ATT TAT 530 Asp Ala Leu Gly Asn Asn Ser Ser Phe His His Arg He Asn He Tyr 160 165 170

GAA ATC ATA AAA CCT GCA ACA GCC AAC TCG AAA TTC CCC GTG ACC AGT 578 Glu He He Lys Pro Ala Thr Ala Asn Ser Lys Phe Pro Val Thr Ser 175 180 185 190

CTT TTG GAC ACC AGG TTG GTG AAT CAG AAT GCA AGC AGG TGG GAA AGT 626 Leu Leu Asp Thr Arg Leu Val Asn Gin Asn Ala Ser Arg Trp Glu Ser 195 200 205

TTT GAT GTC ACC CCC GCT GTG ATG CGG TGG ACT GCA CAG GGA CAC GCC 674 Phe Asp Val Thr Pro Ala Val Met Arg Trp Thr Ala Gin Gly His Ala 210 215 220

AAC CAT GGA TTC GTG GTG GAA GTG GCC CAC TTG GAG GAG AAA CAA GGT 722 Asn His Gly Phe Val Val Glu Val Ala His Leu Glu Glu Lys Gin Gly 225 230 235

GTC TCC AAG AGA CAT GTT AGG ATA AGC AGG TCT TTG CAC CAA GAT GAA 770 Val Ser Lys Arg His Val Arg He Ser Arg Ser Leu His Gin Asp Glu 240 245 250

CAC AGC TGG TCA CAG ATA AGG CCA TTG CTA GTA ACT TTT GGC CAT GAT 818 His Ser Trp Ser Gin He Arg Pro Leu Leu Val Thr Phe Gly His Asp 255 260 265 270

GGA AAA GGG CAT CCT CTC CAC AAA AGA GAA AAA CGT CAA GCC AAA CAC 866 Gly Lys Gly His Pro Leu His Lys Arg Glu Lys Arg Gin Ala Lys His 275 280 285

AAA CAG CGG AAA CGC CTT AAG TCC AGC TGT AAG AGA CAC CCT TTG TAC 914 Lys Gin Arg Lys Arg Leu Lys Ser Ser Cys Lys Arg His Pro Leu Tyr 290 295 300

GTG GAC TTC AGT GAC GTG GGG TGG AAT GAC TGG ATT GTG GCT CCC CCG 962 Val Asp Phe Ser Asp Val Gly Trp Asn Asp Trp He Val Ala Pro Pro 305 310 315

GGG TAT CAC GCC TTT TAC TGC CAC GGA GAA TGC CCT TTT CCT CTG GCT 1010 Gly Tyr His Ala Phe Tyr Cys His Gly Glu Cys Pro Phe Pro Leu Ala 320 325 330

GAT CAT CTG AAC TCC ACT AAT CAT GCC ATT GTT CAG ACG TTG GTC AAC 1058 Asp His Leu Asn Ser Thr Asn His Ala He Val Gin Thr Leu Val Asn 335 340 345 350

TCT GTT AAC TCT AAG ATT CCT AAG GCA TGC TGT GTC CCG ACA GAA CTC 1106 Ser Val Asn Ser Lys He Pro Lys Ala Cys Cys Val Pro Thr Glu Leu 355 360 365

AGT GCT ATC TCG ATG CTG TAC CTT GAC GAG AAT GAA AAG GTT GTA TTA 1154 Ser Ala He Ser Met Leu Tyr Leu Asp Glu Asn Glu Lys Val Val Leu 370 375 380

AAG AAC TAT CAG GAT ATG GTT GTG GAG GGT TGT GGG TGT CGC 1196

Lys Asn Tyr Gin Asp Met Val Val Glu Gly Cys Gly Cys Arg 385 390 395

TAGTACAGCA AAATTAAATA CATAAATATA TATATATATA TATATTTTAG AAAAAAGAAA 1256

AAAA 1260

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 396 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

( i) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Met Val Ala Gly Thr Arg Cys Leu Leu Ala Leu Leu Leu Pro Gin Val 1 5 10 15

Leu Leu Gly Gly Ala Ala Gly Leu Val Pro Glu Leu Gly Arg Arg Lys 20 25 30

Phe Ala Ala Ala Ser Ser Gly Arg Pro Ser Ser Gin Pro Ser Asp Glu 35 40 45

Val Leu Ser Glu Phe Glu Leu Arg Leu Leu Ser Met Phe Gly Leu Lys 50 55 60

Gin Arg Pro Thr Pro Ser Arg Asp Ala Val Val Pro Pro Tyr Met Leu 65 70 75 80

Asp Leu Tyr Arg Arg His Ser Gly Gin Pro Gly Ser Pro Ala Pro Asp 85 90 95

His Arg Leu Glu Arg Ala Ala Ser Arg Ala Asn Thr Val Arg Ser Phe 100 105 110

His His Glu Glu Ser Leu Glu Glu Leu Pro Glu Thr Ser Gly Lys Thr 115 120 125

Thr Arg Arg Phe Phe Phe Asn Leu Ser Ser He Pro Thr Glu Glu Phe 130 135 140

He Thr Ser Ala Glu Leu Gin Val Phe Arg Glu Gin Met Gin Asp Ala 145 150 155 160

Leu Gly Asn Asn Ser Ser Phe His His Arg He Asn He Tyr Glu He 165 170 175

He Lys Pro Ala Thr Ala Asn Ser Lys Phe Pro Val Thr Ser Leu Leu 180 185 190

Asp Thr Arg Leu Val Asn Gin Asn Ala Ser Arg Trp Glu Ser Phe Asp 195 200 205

Val Thr Pro Ala Val Met Arg Trp Thr Ala Gin Gly His Ala Asn His 210 215 220

Gly Phe Val Val Glu Val Ala His Leu Glu Glu Lys Gin Gly Val Ser 225 230 235 240

Lys Arg His Val Arg He Ser Arg Ser Leu His Gin Asp Glu His Ser 245 250 255

Trp Ser Gin He Arg Pro Leu Leu Val Thr Phe Gly His Asp Gly Lys 260 265 270

Gly His Pro Leu His Lys Arg Glu Lys Arg Gin Ala Lys His Lys Gin 275 280 285

Arg Lys Arg Leu Lys Ser Ser Cys Lys Arg His Pro Leu Tyr Val Asp 290 295 300

Phe Ser Asp Val Gly Trp Asn Asp Trp He Val Ala Pro Pro Gly Tyr 305 310 315 320

His Ala Phe Tyr Cys His Gly Glu Cys Pro Phe Pro Leu Ala Asp His 325 330 335

Leu Asn Ser Thr Asn His Ala He Val Gin Thr Leu Val Asn Ser Val 340 345 350

Asn Ser Lys He Pro Lys Ala Cys Cys Val Pro Thr Glu Leu Ser Ala 355 360 365

He Ser Met Leu Tyr Leu Asp Glu Asn Glu Lys Val Val Leu Lys Asn 370 375 380

Tyr Gin Asp Met Val Val Glu Gly Cys Gly Cys Arg 385 390 395

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 574 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(Vi) ORIGINAL SOURCE:

(A) ORGANISM: HOMO SAPIENS

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..327

(D) OTHER INFORMATION: /product- "MATURE hBMP3 (PARTIAL)"

/note- "THIS PARTIAL SEQUENCE OF THE MATURE HUMAN BMP3 PROTEIN INCLUDES THE FIRST THREE CYSTEINES OF THE CONSERVED 7 CYSTEINE SKELETON. SEE U.S. PAT. NO. 5,011,691 FOR 102 C-TERMINAL SEQUENCE (CBMP3.)" (ix) FEATURE:

(A) NAME/KEY: intron

(B) LOCATION: 328.-574

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CGA GCT TCT AAA ATA GAA TAC CAG TAT AAA AAG GAT GAG GTG TGG GAG 48 Arg Ala Ser Lys He Glu Tyr Gin Tyr Lys Lys Asp Glu Val Trp Glu 1 5 10 15

GAG AGA AAG CCT TAC AAG ACC CTT CAG GGC TCA GGC CCT GAA AAG AGT 96 Glu Arg Lys Pro Tyr Lys Thr Leu Gin Gly Ser Gly Pro Glu Lys Ser 20 25 30

AAG AAT AAA AAG AAA CAG AGA AAG GGG CCT CAT CGG AAG AGC CAG ACG 144 Lys Asn Lys Lys Lys Gin Arg Lys Gly Pro His Arg Lys Ser Gin Thr 35 40 45

CTC CAA TTT GAT GAG CAG ACC CTG AAA AAG GCA AGG AGA AAG CAG TGG 192 Leu Gin Phe Asp Glu Gin Thr Leu Lys Lys Ala Arg Arg Lys Gin Trp 50 55 60

ATT GAA CCT CGG AAT TGC GCC AGG AGA TAC CTC AAG GTA GAC TTT GCA 240 He Glu Pro Arg Asn Cys Ala Arg Arg Tyr Leu Lys Val Asp Phe Ala 65 70 75 80

GAT ATT GGC TGG AGT GAA TGG ATT ATC TCC CCC AAG TCC TTT GAT GCC 288 Asp He Gly Trp Ser Glu Trp He He Ser Pro Lys Ser Phe Asp Ala 85 90 95

TAT TAT TGC TCT GGA GCA TGC CAG TTC CCC ATG CCA AAG GTAGCCATTG 337 Tyr Tyr Cys Ser Gly Ala Cys Gin Phe Pro Met Pro Lys 100 105

TTCTCTGTCC TGTACTTACT TCCTATTTCC ATTAGTAGAA AGACACATTG ACTAAGTTAG 397

TGTGCATATA GGGGGTTTGT GTAAGTGTTT GTGTTTCCAT TTGCAAAATC CATTGGGACC 457

CTTATTTACT ACATTCTAAA CCATAATAGG TAATATGGTT ATTCTTGGTT TCTCTTTAAT 517

GGTTGTTAAA GTCATATGAA GTCAGTATTG GTATAAAGAA GGATATGAGA AAAAAAA 574

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 109 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Arg Ala Ser Lys He Glu Tyr Gin Tyr Lys Lys Asp Glu Val Trp Glu 1 5 10 15

Glu Arg Lys Pro Tyr Lys Thr Leu Gin Gly Ser Gly Pro Glu Lys Ser 20 25 30

Lys Asn Lys Lys Lys Gin Arg Lys Gly Pro His Arg Lys Ser Gin Thr 35 40 45

Leu Gin Phe Asp Glu Gin Thr Leu Lys Lys Ala Arg Arg Lys Gin Trp 50 55 60

He Glu Pro Arg Asn Cys Ala Arg Arg Tyr Leu Lys Val Asp Phe Ala 65 70 75 80

Asp He Gly Trp Ser Glu Trp He He Ser Pro Lys Ser Phe Asp Ala 85 90 95

Tyr Tyr Cys Ser Gly Ala Cys Gin Phe Pro Met Pro Lys 100 105

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1788 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: HOMO SAPIENS (F) TISSUE TYPE: HIPPOCAMPUS

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 403..1626

(C) IDENTIFICATION METHOD: experimental

(D) OTHER INFORMATION: /function- "OSTEOGENIC PROTEIN"

/product- "BMP2B" /evidence- EXPERIMENTAL /note- "BMP2B (CDNA)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GAATTCGGGG CAGAGGAGGA GGGAGGGAGG GAAGGAGCGC GGAGCCCGGC CCGGAAGCTA 60

GGTGAGTGTG GCATCCGAGC TGAGGGACGC GAGCCTGAGA CGCCGCTGCT GCTCCGGCTG 120

AGTATCTAGC TTGTCTCCCC GATGGGATTC CCGTCCAAGC TATCTCGAGC CTGCAGCGCC 180

ACAGTCCCCG GCCCTCGCCC AGGTTCACTG CAACCGTTCA GAGGTCCCCA GGAGCTGCTG 240

CTGGCGAGCC CGCTACTGCA GGGACCTATG GAGCCATTCC GTAGTGCCAT CCCGAGCAAC 300

GCACTGCTGC AGCTTCCCTG AGCCTTTCCA GCAAGTTTGT TCAAGATTGG CTGTCAAGAA 360

TCATGGACTG TTATTATATG CCTTGTTTTC TGTCAAGACA CC ATG ATT CCT GGT 414

Met He Pro Gly 1

AAC CGA ATG CTG ATG GTC GTT TTA TTA TGC CAA GTC CTG CTA GGA GGC 462 Asn Arg Met Leu Met Val Val Leu Leu Cys Gin Val Leu Leu Gly Gly 5 10 15 20

GCG AGC CAT GCT AGT TTG ATA CCT GAG ACG GGG AAG AAA AAA GTC GCC 510 Ala Ser His Ala Ser Leu He Pro Glu Thr Gly Lys Lys Lys Val Ala 25 30 35

GAG ATT CAG GGC CAC GCG GGA GGA CGC CGC TCA GGG CAG AGC CAT GAG 558 Glu He Gin Gly His Ala Gly Gly Arg Arg Ser Gly Gin Ser His Glu 40 45 50

CTC CTG CGG GAC TTC GAG GCG ACA CTT CTG CAG ATG TTT GGG CTG CGC 606 Leu Leu Arg Asp Phe Glu Ala Thr Leu Leu Gin Met Phe Gly Leu Arg 55 60 65

CGC CGC CCG CAG CCT AGC AAG AGT GCC GTC ATT CCG GAC TAC ATG CGG 654 Arg Arg Pro Gin Pro Ser Lys Ser Ala Val He Pro Asp Tyr Met Arg 70 75 80

GAT CTT TAC CGG CTT CAG TCT GGG GAG GAG GAG GAA GAG CAG ATC CAC 702 Asp Leu Tyr Arg Leu Gin Ser Gly Glu Glu Glu Glu Glu Gin He His 85 90 95 100

AGC ACT GGT CTT GAG TAT CCT GAG CGC CCG GCC AGC CGG GCC AAC ACC 750 Ser Thr Gly Leu Glu Tyr Pro Glu Arg Pro Ala Ser Arg Ala Asn Thr 105 110 115

GTG AGG AGC TTC CAC CAC GAA GAA CAT CTG GAG AAC ATC CCA GGG ACC 798 Val Arg Ser Phe His His Glu Glu His Leu Glu Asn He Pro Gly Thr 120 125 130

AGT GAA AAC TCT GCT TTT CGT TTC CTC TTT AAC CTC AGC AGC ATC CCT 846 Ser Glu Asn Ser Ala Phe Arg Phe Leu Phe Asn Leu Ser Ser He Pro 135 140 145

GAG AAC GAG GTG ATC TCC TCT GCA GAG CTT CGG CTC TTC CGG GAG CAG 894 Glu Asn Glu Val He Ser Ser Ala Glu Leu Arg Leu Phe Arg Glu Gin 150 155 160

GTG GAC CAG GGC CCT GAT TGG GAA AGG GGC TTC CAC CGT ATA AAC ATT 942 Val Asp Gin Gly Pro Asp Trp Glu Arg Gly Phe His Arg He Asn He 165 170 175 180

TAT GAG GTT ATG AAG CCC CCA GCA GAA GTG GTG CCT GGG CAC CTC ATC 990 Tyr Glu Val Met Lys Pro Pro Ala Glu Val Val Pro Gly His Leu He 185 190 195

ACA CGA CTA CTG GAC ACG AGA CTG GTC CAC CAC AAT GTG ACA CGG TGG 1038 Thr Arg Leu Leu Asp Thr Arg Leu Val His His Asn Val Thr Arg Trp 200 205 210

GAA ACT TTT GAT GTG AGC CCT GCG GTC CTT CGC TGG ACC CGG GAG AAG 1086 Glu Thr Phe Asp Val Ser Pro Ala Val Leu Arg Trp Thr Arg Glu Lys 215 220 225

CAG CCA AAC TAT GGG CTA GCC ATT GAG GTG ACT CAC CTC CAT CAG ACT 1134 Gin Pro Asn Tyr Gly Leu Ala He Glu Val Thr His Leu His Gin Thr 230 235 240

CGG ACC CAC CAG GGC CAG CAT GTC AGG ATT AGC CGA TCG TTA CCT CAA 1182 Arg Thr His Gin Gly Gin His Val Arg He Ser Arg Ser Leu Pro Gin 245 250 255 260

GGG AGT GGG AAT TGG GCC CAG CTC CGG CCC CTC CTG GTC ACC TTT GGC 1230 Gly Ser Gly Asn Trp Ala Gin Leu Arg Pro Leu Leu Val Thr Phe Gly 265 270 275

CAT GAT GGC CGG GGC CAT GCC TTG ACC CGA CGC CGG AGG GCC AAG CGT 1278 His Asp Gly Arg Gly His Ala Leu Thr Arg Arg Arg Arg Ala Lys Arg 280 285 290

AGC CCT AAG CAT CAC TCA CAG CGG GCC AGG AAG AAG AAT AAG AAC TGC 1326 Ser Pro Lys His His Ser Gin Arg Ala Arg Lys Lys Asn Lys Asn Cys 295 300 305

CGG CGC CAC TCG CTC TAT GTG GAC TTC AGC GAT GTG GGC TGG AAT GAC 1374 Arg Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn Asp 310 315 320

TGG ATT GTG GCC CCA CCA GGC TAC CAG GCC TTC TAC TGC CAT GGG GAC 1422 Trp He Val Ala Pro Pro Gly Tyr Gin Ala Phe Tyr Cys His Gly Asp 325 330 335 340

TGC CCC TTT CCA CTG GCT GAC CAC CTC AAC TCA ACC AAC CAT GCC ATT 1470 Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr Asn His Ala He 345 350 355

GTG CAG ACC CTG GTC AAT TCT GTC AAT TCC AGT ATC CCC AAA GCC TGT 1518 Val Gin Thr Leu Val Asn Ser Val Asn Ser Ser He Pro Lys Ala Cys 360 365 370

TGT GTG CCC ACT GAA CTG AGT GCC ATC TCC ATG CTG TAC CTG GAT GAG 1566 Cys Val Pro Thr Glu Leu Ser Ala He Ser Met Leu Tyr Leu Asp Glu 375 380 385

TAT GAT AAG GTG GTA CTG AAA AAT TAT CAG GAG ATG GTA GTA GAG GGA 1614 Tyr Asp Lys Val Val Leu Lys Asn Tyr Gin Glu Met Val Val Glu Gly 390 395 400

TGT GGG TGC CGC TGAGATCAGG CAGTCCTTGA GGATAGACAG ATATACACAC 1666

Cys Gly Cys Arg

405

ACACACACAC ACACCACATA CACCACACAC ACACGTTCCC ATCCACTCAC CCACACACTA 1726

CACAGACTGC TTCCTTATAG CTGGACTTTT ATTTAAAAAA AAAAAAAAAA AAACCCGAAT 1786

TC 1788

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 408 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Met He Pro Gly Asn Arg Met Leu Met Val Val Leu Leu Cys Gin Val 1 5 10 15

Leu Leu Gly Gly Ala Ser His Ala Ser Leu He Pro Glu Thr Gly Lys 20 25 30

Lys Lys Val Ala Glu He Gin Gly His Ala Gly Gly Arg Arg Ser Gly 35 40 45

Gin Ser His Glu Leu Leu Arg Asp Phe Glu Ala Thr Leu Leu Gin Met 50 55 60

Phe Gly Leu Arg Arg Arg Pro Gin Pro Ser Lys Ser Ala Val He Pro 65 70 75 80

Asp Tyr Met Arg Asp Leu Tyr Arg Leu Gin Ser Gly Glu Glu Glu Glu 85 90 95

Glu Gin He His Ser Thr Gly Leu Glu Tyr Pro Glu Arg Pro Ala Ser 100 105 110

Arg Ala Asn Thr Val Arg Ser Phe His His Glu Glu His Leu Glu Asn 115 120 125

He Pro Gly Thr Ser Glu Asn Ser Ala Phe Arg Phe Leu Phe Asn Leu 130 135 140

Ser Ser He Pro Glu Asn Glu Val He Ser Ser Ala Glu Leu Arg Leu 145 150 155 160

Phe Arg Glu Gin Val Asp Gin Gly Pro Asp Trp Glu Arg Gly Phe His 165 170 175

Arg He Asn He Tyr Glu Val Met Lys Pro Pro Ala Glu Val Val Pro 180 185 190

Gly His Leu He Thr Arg Leu Leu Asp Thr Arg Leu Val His His Asn 195 200 205

Val Thr Arg Trp Glu Thr Phe Asp Val Ser Pro Ala Val Leu Arg Trp 210 215 220

Thr Arg Glu Lys Gin Pro Asn Tyr Gly Leu Ala He Glu Val Thr His 225 230 235 240

Leu His Gin Thr Arg Thr His Gin Gly Gin His Val Arg He Ser Arg 245 250 255

Ser Leu Pro Gin Gly Ser Gly Asn Trp Ala Gin Leu Arg Pro Leu Leu 260 265 270

Val Thr Phe Gly His Asp Gly Arg Gly His Ala Leu Thr Arg Arg Arg 275 280 285

Arg Ala Lys Arg Ser Pro Lys His His Ser Gin Arg Ala Arg Lys Lys 290 295 300

Asn Lys Asn Cys Arg Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val 305 310 315 320

Gly Trp Asn Asp Trp He Val Ala Pro Pro Gly Tyr Gin Ala Phe Tyr 325 330 335

Cys His Gly Asp Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr 340 345 350

Asn His Ala He Val Gin Thr Leu Val Asn Ser Val Asn Ser Ser He 355 360 365

Pro Lys Ala Cys Cys Val Pro Thr Glu Leu Ser Ala He Ser Met Leu 370 375 380

Tyr Leu Asp Glu Tyr Asp Lys Val Val Leu Lys Asn Tyr Gin Glu Met 385 390 395 400

Val Val Glu Gly Cys Gly Cys Arg 405

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 102 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(A) ORGANISM: HOMO SAPIENS

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..102

(D) OTHER INFORMATION: /note- "BMP5"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg Asp Leu Gly Trp Gin 1 5 10 15

Asp Trp He He Ala Pro Glu Gly Tyr Ala Ala Phe Tyr Cys Asp Gly 20 25 30

Glu Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala 35 40 45

He Val Gin Thr Leu Val His Leu Met Phe Pro Asp His Val Pro Lys 50 55 60

Pro Cys Cys Ala Pro Thr Lys Leu Asn Ala He Ser Val Leu Tyr Phe 65 70 75 80

Asp Asp Ser Ser Asn Val He Leu Lys Lys Tyr Arg Asn Met Val Val 85 90 95

Arg Ser Cys Gly Cys His 100

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 102 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

( i) ORIGINAL SOURCE:

(A) ORGANISM: HOMO SAPIENS

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..102

(D) OTHER INFORMATION: /note- "BMP6"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Cys Arg Lys His Glu Leu Tyr Val Ser Phe Gin Asp Leu Gly Trp Gin 1 5 10 15

Asp Trp He He Ala Pro Lys Gly Tyr Ala Ala Asn Tyr Cys Asp Gly 20 25 30

Glu Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala 35 40 45

He Val Gin Thr Leu Val His Leu Met Asn Pro Glu Tyr Val Pro Lys 50 55 60

Pro Cys Cys Ala Pro Thr Lys Leu Asn Ala He Ser Val Leu Tyr Phe 65 70 75 80

Asp Asp Asn Ser Asn Val He Leu Lys Lys Tyr Arg Trp Met Val Val 85 90 95

Arg Ala Cys Gly Cys His 100

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 102 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..102

(D) OTHER INFORMATION: /label- OPX

/note- "WHEREIN XAA AT EACH POS'N IS INDEPENDENTLY SELECTED FROM THE RESIDUES OCCURRING AT THE CORRESPONDING POS'N IN THE C-TERMINAL SEQUENCE OF MOUSE OR HUMAN OPl OR OP2 (SEE SEQ. ID NOS. 1,8,10 AND 12.)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Cys Xaa Xaa His Glu Leu Tyr Val Xaa Phe Xaa Asp Leu Gly Trp Xaa 1 5 10 15

Asp Trp Xaa He Ala Pro Xaa Gly Tyr Xaa Ala Tyr Tyr Cys Glu Gly 20 25 30

Glu Cys Xaa Phe Pro Leu Xaa Ser Xaa Met Asn Ala Thr Asn His Ala 35 40 45

He Xaa Gin Xaa Leu Val His Xaa Xaa Xaa Pro Xaa Xaa Val Pro Lys 50 55 60

Xaa Cys Cys Ala Pro Thr Xaa Leu Xaa Ala Xaa Ser Val Leu Tyr Xaa 65 70 75 80

Asp Xaa Ser Xaa Asn Val Xaa Leu Xaa Lys Xaa Arg Asn Met Val Val 85 90 95

Xaa Ala Cys Gly Cys His 100